

THE
POWER
OF
ONE
2024

CONSOLIDATING OUR STRENGTHS

CENTRALIZING OUR VISION

ANNUAL REPORT

United CIIGMA Institute of Medical Sciences
Private Limited

UNITED CIIGMA INSTITUTE OF MEDICAL SCIENCES PRIVATE LIMITED

FOURTEENTH ANNUAL REPORT 2023-24

CORPORATE INFORMATION

BOARD OF DIRECTORS

Dr. Unmesh Vidyadhar Takalkar	- Managing Director
Ms. Ekta Bahl	- Independent Director
Mr. Kewal Handa	- Independent Director
Mr. Jasdeep Singh	- Non-executive Director
Mr. Varun Shadilal Khanna	- Non-executive Director
Mr. Tejas Naphade	- Non-executive Director
Mr. Mahadevan Narayanamoni	- Non-executive Director
Dr. Manisha Unmesh Takalkar	- Non-executive Director

Mr. Anand V	-Chief Financial Officer
Ms. Divyanki Sharma	-Company Secretary

BOARD COMMITTEES

Audit Committee

Ms. Ekta Bahl	- Chairperson
Mr. Kewal Kundanlal Handa	- Member
Mr. Mahadevan Narayanamoni	- Member

Nomination and Remuneration Committee

Ms. Ekta Bahl	- Chairperson
Mr. Kewal Kundanlal Handa	- Member
Mr. Jasdeep Singh	- Member
Dr. Manisha Takalkar	- Member

Operating Committee

Mr. Jasdeep Singh	- Chairperson
Dr. Unmesh Vidyadhar Takalkar	- Member
Dr. Manisha Unmesh Takalkar	- Member
Dr. Shashikanth Aggsare	- Member

REGISTERED OFFICE

Plot No. 6 & 7, Survey No.10,
Shahanoorwadi, Dargah Road,
Aurangabad Maharashtra, India – 431001

CORPORATE OFFICE

CARE Corporate Office
1st Floor, Kohinoor Building, Opp: Park Hyatt,
Road No. 2, Banjara Hills, Hyderabad, Telangana, India- 500043

STATUTORY AUDITORS

M/s. Price Waterhouse Chartered Accountants LLP
Unit -2B, 8th Floor, Octave Block, Block E1, Parcel-4,
Salarpuria Sattva Knowledge City,
Raidurg, Hyderabad – 500 081 Telangana

COST AUDITORS

M/s. Nageswara Rao & Co
Cost Accountants
H.No.30-1569/2, Plot No.35, Anantanagar Colony
Neredmet, Secunderabad.

INTERNAL AUDITORS

Ernst & Young LLP
18, iLabs Centre, Madhapur,
Hyderabad – 500 081 Telangana

SECRETARIAL AUDITORS

RISHABH J & ASSOCIATES
Company Secretaries
1/7271, G/F, Plot No 4, KH No. 27,
East Gorakh Park, Delhi, NCT Delhi- 110032

UNITED CIIGMA INSTITUTE OF MEDICAL SCIENCES PRIVATE LIMITED

CIN: U74120MH2011PTC213136

Registered office address: Plot No 6 & 7, Survey No 10, Shahanoorwadi,
Dargah Road, Aurangabad, Maharashtra, India – 431005, Tel 0240-2366666, 6676666

Email: cs.office@carehospitals.com, Website: www.ciigmagroup.org

NOTICE

NOTICE is hereby given that the 14th Annual General Meeting of the members of **United Ciigma Institute of Medical Sciences Private Limited (“Company”)** will be held on Thursday, 26th September, 2024 at 11:00 A.M. through Video Conferencing (VC)/Other Audio Visual means (OAVM) facility at the Registered Office of the Company situated at Plot No 6 & 7, Survey No 10, Shahanoorwadi, Dargah Road, Aurangabad, Maharashtra, India – 431005 to transact the following business:

ORDINARY BUSINESS(ES):

1. To receive, consider and adopt the audited financial statements i.e., Balance Sheet, the Statement of Profit & Loss account and cash flow statement of the Company for the financial year ended 31st March, 2024 and the Reports of the Auditors and Board of Directors thereon.
2. To appoint a Director in place of Dr. Unmesh Vidyadhar Takalkar (DIN: 01578381), who retires by rotation and being eligible, offers his candidature for re-appointment.
3. To appoint a Director in place of Mr. Mahadevan Narayanamoni (DIN: 07128788), who retires by rotation and being eligible, offers his candidature for re-appointment.

SPECIAL BUSINESS(ES):

4. **To Appoint Mr. Tejas Deepak Naphade (DIN: 10219144) as a Director of the Company.**

To consider and if thought fit, to pass the following resolution with or without modification as an Ordinary Resolution

“RESOLVED THAT Mr. Tejas Deepak Naphade (DIN: 10219144) who was appointed as an Additional Director of the Company w.e.f. November 17, 2023 by the Board of Directors in terms of Section 161(1) and other applicable provisions of the Companies Act 2013, (including any statutory modifications or re-enactments thereof) and other applicable provisions of Articles of Association of the Company, and who holds such office upto this Annual General Meeting, be and is hereby appointed as Non-Executive Director of the Company, who shall be liable to retire by rotation.

RESOLVED FURTHER THAT Board of Directors, be and are hereby severally authorized to do all such acts, deeds, matters and things as may be necessary, proper, expedient, required or incidental thereto, in this regard including but not limited to filing of requisite application/forms/ reports, etc. with the Ministry of Corporate Affairs or with such other authorities as may be required for the purpose of giving effect to this resolution.”

5. **To Appoint Mr. Varun Shadilal Khanna (DIN: 09255301) as a Director of the Company.**

To consider and if thought fit, to pass the following resolution with or without modification as an Ordinary Resolution

“RESOLVED THAT Mr. Varun Shadilal Khanna (DIN: 09255301) who was appointed as an Additional Director of the Company w.e.f. May 29, 2024 by the Board of Directors in terms of Section 161(1) and

other applicable provisions of the Companies Act 2013, (including any statutory modifications or re-enactments thereof) and other applicable provisions of Articles of Association of the Company, and who holds such office upto this Annual General Meeting, be and is hereby appointed as Non-Executive Director of the Company, who shall be liable to retire by rotation.

RESOLVED FURTHER THAT Board of Directors, be and are hereby severally authorized to do all such acts, deeds, matters and things as may be necessary, proper, expedient, required or incidental thereto, in this regard including but not limited to filing of requisite application/forms/ reports, etc. with the Ministry of Corporate Affairs or with such other authorities as may be required for the purpose of giving effect to this resolution.”

6. To Ratify the Remuneration Payable to Cost Auditors:

To consider and, if thought fit, to pass with or without modification(s) the following resolution as an Ordinary Resolution:

“**RESOLVED THAT** pursuant to the provisions of Section 148 and other applicable provisions, if any, of the Companies Act, 2013 read with the Companies(Audit and Auditors) Rules, 2014, (including any statutory modification(s) or re-enactment thereof, for the time being in force), the remuneration payable to Cost Auditors M/s. Nageswara Rao & Co., Cost Accountants having Firm Registration No: 000332, appointed by the Board of Directors on the recommendation of Audit Committee as Cost Auditor, to conduct audit of cost records of the Company for the financial year 2024-25 amounting to Rs 25,000/- (Rupees Twenty Five Thousand Only) Per Annum plus applicable taxes and out of pocket expenses at actual in connection with the aforesaid audit, be and is hereby ratified and approved.

RESOLVED FURTHER THAT the Board of Directors, be and are hereby severally authorized to do all such acts, deeds, matters and things as may be necessary, proper, expedient, required or incidental thereto, in this regard including but not limited to filing of requisite application/forms/ reports, etc. with the Ministry of Corporate Affairs or with such other authorities as may be required for the purpose of giving effect to this resolution.”

For and on behalf of Board of Directors



Jasdeep Singh
Director & Group CEO
DIN: 02705303
Email: jasdeep.singh@carehospitals.com

Date: 21-08-2024
Place: Hyderabad

Notes:

1. The explanatory statement pursuant to Section 102 of the Companies Act, 2013 ("the Act") relating to Special Business i.e., Item No. 4,5 and 6 to be transacted at Annual General Meeting is annexed hereto.
2. The Ministry of Corporate Affairs ("MCA") has vide General circular No. 14/2020 dated 08.04.2020, 17/2020 dated 13.04.2020, 22/2020 dated 15.06.2020, 33/2020 dated 28.09.2020 and 39/2020 dated 31.12.2020 and 10/2021 dated 23.06.2021, read with circulars No. 21/2021 dated 8.12.2021, General circular no. 2/2022 dated 05.05.2022 and General circular no. 10/2022 dated 28.12.2022 (collectively referred to as "MCA Circulars") permitted the holding of the Annual General Meeting ("AGM") through VC / OAVM, without the physical presence of the Members till 30th September, 2024. In compliance with the provisions of the Companies Act, 2013 ("Act") and MCA Circulars and relevant circulars and other applicable provisions, the AGM of the Company is being held through VC / OAVM. The proceedings of the Annual General Meeting will be deemed to be conducted at the Registered office of the Company at Plot No 6 & 7, Survey No 10, Shahanoorwadi, Dargah Road, Aurangabad, Maharashtra, India – 431005.
3. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.
4. **Pursuant to the provisions of the Act, a member entitled to attend and vote at the AGM is entitled to appoint a proxy to attend and vote on his/her behalf and the proxy need not be a Member of the Company. Since this AGM is being held pursuant to the MCA Circulars through VC / OAVM, physical attendance of Members has been dispensed with. Accordingly, the facility for appointment of proxies by the Members will not be available for the AGM and hence the Proxy Form and Attendance Slip are not annexed to this Notice.**
5. Members desiring to seek any information/clarifications on the Financial Statements are requested to write to the Company at least seven (7) days before the Annual General Meeting to enable the management to keep the information ready.
6. Institutional / Corporate Shareholders (i.e. other than individuals / HUF, NRI, etc.) entitled to appoint authorized representatives to attend the AGM through VC/OAVM and participate there at and cast their votes. Institutional / Corporate Shareholders are requested to send a scanned copy (PDF/JPG Format) of its certified true copy of Board or governing body Resolution/Authorization/Power of Attorney etc., alongwith the specimen signature of the authorized representative who is authorized to attend the AGM on its behalf and to vote pursuant to Section 113 of the Act. The said Resolution/Authorization shall be sent to the Company by email through its registered email address to cs.office@carehospitals.com
7. Members holding shares in physical/dematerialized mode, who have not registered/updated their email addresses with the Company are requested to register/update their email addresses by writing to the Company along with their details and folio number at cs.office@carehospitals.com
8. Members whose email ids are already registered with the Company or with Registrar and Share transfer agent will receive the Zoom Link (for video conferencing) for attending the Annual General Meeting which is also given below; Members are requested to attend the meeting through the given link and In case any member has not received the link via email then they are requested to send a mail from their E-mail account and write to cs.office@carehospitals.com.

Zoom Link:

Topic: UCIMSPL- Annual General Meeting 2024

Time: September 26, 2024 at 11:00 A.M, India

Join Zoom Meeting

<https://us02web.zoom.us/j/86070344278?pwd=iI73gDKJY8CuF9SLa9bp8xpF1F7fmz.1>

Meeting ID: 860 7034 4278
Passcode: 242630

Instructions:

a) Type the exact link given above in the web address bar and enter

Or

b) i) open Google Chrome/Mozilla Firefox/Internet Explorer

ii) Go to join.zoom.us and type

Meeting ID: 860 7034 4278

Passcode: 242630

iii) Click **Join**

In case of any technical difficulties write to - udaykumar.bellapu@carehospitals.com; or cs.office@carehospitals.com;

9. In keeping with Ministry of Corporate Affairs' Green initiative measures, the Company hereby requests members who have not registered their email addresses so far, to register their email addresses for receiving all communication including annual report, notices, circulars, etc. from the Company electronically by writing to cs.office@carehospitals.com.
10. The statutory registers including register of directors and key managerial personnel and their shareholding, the register of contracts or arrangements in which directors are interested maintained under the Companies Act, 2013 and all other documents referred to in the notice will be available for inspection in electronic mode. Members who wish to inspect the register are requested to write to the company by sending e-mail to cs.office@carehospitals.com
11. All shareholders attending the AGM will have the option to post their comments/queries through a dedicated chat box, which will be made available.
12. The Annual Report of the Company including the Notice convening the AGM circulated to the members of the Company will be available on the Company's website at <https://www.carchospitals.com/annual-reports>
13. Since the AGM will be held through VC / OAVM, the Route Map is not annexed in this Notice and this statement shall be considered the compliance of Secretarial Standard-2.

Explanatory Statement
(Under Section 102(1) of the Companies Act, 2013)

Item No. 4 & 5:

The Board appointed Mr. Tejas Deepak Naphade (DIN: 10219144) and Mr. Varun Shadilal Khanna (DIN: 03584124) as an Additional Directors of the Company with effect from November 17, 2023 and May 29, 2024 respectively, and they hold the office till ensuing Annual General Meeting.

In terms of Section 160 of the Companies Act, 2013, the Company has received notices in writing from Member(s) proposing their candidature.

Other than Director's as mentioned herein above, being appointees, none of the other Directors and Key Managerial Personnel of the Company or their relatives are concerned or interested financially or otherwise, in the resolution(s)

Your Board recommends the resolution set forth in the item no. 4 & 5 of the Notice for approval of the members. by way of an **Ordinary Resolution**.

Item No. 6:

The Board of Directors, on the recommendation of Audit Committee, at its meeting held on August 21, 2024, approved the appointment of M/s. Nageswara Rao & Co. (Firm Registration Number- 000332), as Cost Auditor, to conduct the audit of cost records of the Company for the financial year 2024-25 at a remuneration of 25,000/- (Rupees Twenty Five Thousand Only) per annum plus applicable taxes and out of pocket expenses at actuals

In accordance with the provisions of Section 148(3) of the Companies Act, 2013 read with Rule 14 of the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), the remuneration payable to the Cost Auditor as recommended by the Audit Committee and approved by the Board of Directors has to be ratified by the members of the Company at a general meeting. Accordingly, consent of the members is being sought for ratification of the remuneration payable to the Cost Auditor for the financial year 2024-25.

None of the Directors / Key Managerial Personnel / their relatives is, in any way, concerned or interested, financially or otherwise, in this resolution.

Your Board recommends the resolution set forth in the item no.6 of the Notice for approval of the Members by way of **Ordinary Resolution**.

For and on behalf of Board of Directors



Jasdeep Singh
Director & Group CEO
DIN: 02705303
Email: jasdeep.singh@carehospitals.com

Date: 21-08-2024
Place: Hyderabad

BOARD'S REPORT

Dear Members,

On behalf of the Board of Directors, we take pleasure in presenting the 14th (Fourteenth) Annual Report of your Company along with the Audited Financial Statements and the Auditors' Report thereon, for the Financial Year ("FY") ended 31st March, 2024.

1. REVIEW OF OPERATIONS

During the Financial Year 2023-24, the Company achieved a turnover of INR 1,392.76 Mn. The profit before Interest, depreciation and tax (EBITDA) is INR 353.36 Mn. and the Net profit after, depreciation, finance cost and tax is INR 106.41 Mn.

FINANCIAL PERFORMANCE FOR THE YEAR UNDER REVIEW

(Rupees in Millions)

Particulars	As at 31 March	
	2024	2023
Net Sales / Income from:		
Business Operations	1,392.76	1,237.04
Other Income	34.01	19.26
Total Income	1,426.77	1,256.30
Less: Expenditure	1,073.41	894.85
EBITDA	353.36	361.45
Less: Depreciation	126.61	118.33
Less: Finance cost	86.91	126.12
Profit before Tax	139.84	90.23
Less: Current Income Tax	19.58	-
Less: MAT Credit	(19.58)	-
Less: Deferred Tax	33.43	18.23
Net Profit after Tax	106.41	72.00
Other Comprehensive Income:		
(i) Items that will not be reclassified subsequently to profit or loss	0.15	
a. Remeasurement of defined benefit plan		0.38
(ii) Income Tax relating to items that will not be reclassified to profit or loss	(0.04)	(0.10)
Total Comprehensive Income for the Year	106.52	72.28
Earnings per share (Basic & Diluted)		
Basic Earnings per equity share (in ₹)	2.07	1.57
Diluted Earnings per equity share (in ₹)	2.07	1.57

2. CHANGE IN THE NATURE OF BUSINESS

During the Financial year under review, there was no change in the nature of business of the Company.

3. DIVIDEND

The Board of Directors of your Company has not recommended any dividend for the financial year 2023-24. The current year profits are ploughed back for expansion plans of the Company.

4. MATERIAL CHANGES AND COMMITMENT IF ANY AFFECTING THE FINANCIAL POSITION OF THE COMPANY OCCURRED BETWEEN THE END OF THE FINANCIAL YEAR TO WHICH THIS FINANCIAL STATEMENTS RELATE AND THE DATE OF THE REPORT

No material changes and commitments affecting the financial position of the Company occurred between the end of the Financial Year and the date of this report.

5. TRANSFER OF UNCLAIMED DIVIDEND TO INVESTOR EDUCATION AND PROTECTION FUND

In accordance with the provisions of Sections 124 and 125 of the Act and Investor Education and Protection Fund (Accounting, Audit, Transfer and Refund) Rules, 2016 (IEPF Rules), dividends not encashed/claimed within seven years from the date of declaration are to be transferred to the Investor Education and Protection Fund (IEPF).

The amount remaining in the unclaimed dividend account of the Company remains unpaid and unclaimed for a period less than seven years. Therefore, the provisions of Section 125(2) of the Companies Act, 2013 does not apply.

6. TRANSFER TO RESERVES

The details of the amount transferred to the reserves and surplus is detailed in Statement of changes in Equity for the year ended March 31, 2024 and Note No 4.12(b) of the financial statements enclosed herewith.

7. DETAILS OF SUBSIDIARY / JOINT VENTURES / ASSOCIATE COMPANIES

The Company has following 2(two) Subsidiaries as on March 31, 2024. There has been no material change in the nature of business of subsidiaries.

S. No.	Name and address of the Company	CIN/GLN	Holding /Subsidiary/ Associate	% of share held	Applicable Section
1.	United CIIGMA Hospitals Healthcare Private Limited	U85110MH2016PTC279990	Wholly Owned Subsidiary	100%	2(87)
2	Ciigma Institute Of Medical Sciences Private Limited	U85110MH2007PTC172787	Wholly Owned Subsidiary	100%	2(87)

Further, this Company is a subsidiary of Quality Care India Limited.

8. DEPOSITS

The Company has not accepted any public deposits under Sections 73 & 76 of the Companies Act, 2013 read with Companies (Acceptance of Deposits) Rules, 2014 during the year Financial Year 2023-24 under review.

Details relating to deposits covered under Chapter V of the act –

- a. Accepted during the year; - NIL
- b. Remained unpaid or unclaimed as at the end of the year; - NIL
- c. Whether there has been any default in repayment of deposits or payment of interest thereon during the year and if so, number of such cases and the total amount involved- None.
 - i. At the beginning of the year; - NA
 - ii. Maximum during the year; - NA
 - iii. At the end of the year; - NA

9. SHARE CAPITAL

The Authorised Share Capital as on March 31, 2024 was Rs. 52,00,00,000/- consisting of 5,20,00,000 equity shares of Rs. 10/- (Rupees Ten Only) each. The Issued, Paid up & Subscribed Equity Share Capital as on March 31, 2024 was Rs. 51,36,67,110/- consisting of 5,13,66,711 equity shares of Rs. 10/- each.

During the year under review:

- a. the Company has not issued or allotted any Shares.
- b. the Company has not issued shares with differential voting rights.
- c. During the year under review, the company has not undertaken any of the following transactions.

Buy Back of Securities	Sweat Equity	Bonus Shares	Employees Stock Option
Nil	Nil	Nil	Nil

10. DIRECTORS RESPONSIBILITY STATEMENT

In accordance with the provisions of Section 134(5) of the Companies Act, 2013, the Board of Directors, to the best of their knowledge and ability, confirms that:

- i. In the preparation of the annual accounts, the applicable accounting standards have been followed and there are no material departures;
- ii. They have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs and of the profits of the Company for that period;
- iii. They have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act and for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

- iv. They have prepared the annual accounts on a going concern basis;
- v. They have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.
- vi. They have laid down internal financial controls to be followed by the Company and such internal financial controls are adequate and operating effectively;

11. BOARD OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

During the year in accordance with provisions of Section 161(1) of the Companies Act, 2013 Board appointed Mr. Tejas Deepak Naphade (DIN: 10219144) and Mr. Varun Shadilal Khanna (DIN: 03584124) were appointed as Additional Directors of the Company w.e.f. November 17, 2023 and May 29, 2024 respectively and they holds office till the conclusion of ensuing Annual General Meeting and your Board recommends their appointment as Directors of the Company.

Apart from the above, during the year under review, following directors have tendered their resignations from the Board :

- Mr. Vikas Rastogi (DIN: 09622535)- w.e.f. November 17, 2023

Retirement by rotation and subsequent re-appointment

In accordance with the provisions of Section 160 of the Companies Act, 2013 Dr. Unmesh Vidyadhar Takalkar, Managing Director and Mr. Mahadevan Narayanamoni, Director are liable to retire by rotation and being eligible offers herself for appointment.

KEY MANAGERIAL PERSONNEL:

During the year under review and in accordance with the provisions of Section 203 of the Companies Act, 2013, the following changes in the Key Managerial personnel have taken place:

- Appointment of Mr. Anand V as a Chief Financial Officer of the Company w.e.f. November 25, 2023.
- Appointment of Ms. Divyanki Sharma as Company Secretary of the Company w.e.f. January 01, 2024.
- Resignation of Mr. Sachin Subhash Sancheti as Chief Financial Officer of the Company w.e.f. May 31, 2023.
- Resignation of Ms. Priyanka Aggarwal as Company Secretary of the Company w.e.f. July 31, 2023.

12. NUMBER OF MEETINGS OF THE BOARD

A. Board Meetings:

During the year under the review, the Board of directors of the Company met Four (4) times during the year. The details of Board meeting and the attendance of the Board of Directors in such meetings is as follows:-

Details of attendances are as under:

Attendance of Directors at the Board Meetings of the Company held during the year FY 2023-24					
S No	Name of the Director	18.07.2023	21.08.2023	06.12.2023	06.03.2024
1	Mr. Jasdeep Singh	Yes	Yes	Yes	Yes
2	Dr. Unmesh Vidyadhar Takalkar	YES (VC)	YES (VC)	YES (VC)	YES (VC)
3	Mr. Tejas Deepak Naphade ²	NA	NA	YES (VC)	YES (VC)
4	Ms. Ekta Bahl	YES (VC)	YES (VC)	YES (VC)	YES (VC)
5	Mr. Kewal Handa	YES (VC)	YES (VC)	YES (VC)	YES (VC)
6	Mr. Mahadevan Narayanamoni	YES (VC)	YES (VC)	YES (VC)	YES (VC)
7	Dr. Manisha Unmesh Takalkar	YES (VC)	YES (VC)	LOA	LOA
8	Mr. Vikas Rastogi ¹	Yes	Yes	Resigned	Resigned

¹ Mr. Vikas Rastogi Resigned as director of the Company w.e.f 17.11.2023

² Mr. Tejas Deepak Naphade, appointed as Additional director of the Company w.e.f 17.11.2023

B. Number of Committee Meetings –

i. Audit Committee Meeting:

The Audit Committee is constituted with following members:

- Ms. Ekta Bahl - Chairperson
- Mr. Kewal Handa - Member
- Mr. Mahadevan Narayanamoni - Member

The Audit Committee of the Company had met Two (2) times during the year

S. No	Director	18-07-2023	21-08-2023
1	Ms. Ekta Bahl	Yes (VC)	Yes (VC)
2	Mr. Kewal Handa	Yes (VC)	Yes (VC)
3	Mr. Mahadevan Narayanamoni	Yes (VC)	Yes (VC)

ii. Nomination and Remuneration Committee (NRC):

The Nomination and Remuneration Committee is constituted with following members:

- Ms. Ekta Bahl - Chairperson
- Mr. Kewal Handa - Member
- Mr. Jasdeep Singh - Member
- Dr. Manisha Unmesh Takalkar - Member

The Nomination and Remuneration Committee of the Company had met Two (2) time during the year

S.No	Director	21-08-2023	06-12-2023
1	Ms. Ekta Bahl	Yes (VC)	Yes (VC)
2	Mr. Kewal Handa	Yes (VC)	Yes (VC)
3	Mr. Jasdeep Singh	Yes	Yes
4	Dr. Manisha Unmesh Takalkar	Yes (VC)	Yes (VC)

iii. Corporate Social Responsibility Committee (CSR):

As per provisions of Section 135(9) of the Companies Act, 2013, it is not mandatory to constitute a CSR Committee for the Company where the amount CSR spent does not exceed Rs.50 Lakh and the Board of Directors of the Company shall discharge the functions of the CSR Committee. Therefore, the CSR Committee of the Company stand dissolved by passing the board resolution in the meeting held on 6th December, 2022.

iv. Meeting of Independent Directors:

S.No	Director	06-03-2024
1	Ms. Ekta Bahl	Yes (VC)
2	Mr. Kewal Handa	Yes (VC)

13. STATEMENT ON DECLARATION BY INDEPENDENT DIRECTOR

Your Company has received declarations from all independent directors of the Company confirming that they meet with the criteria of independence as prescribed under sub-section 6 of section 149 of the Companies Act, 2013. The independent Directors have duly complied with the code for Independent Directors prescribed in Schedule IV to the Act.

In the opinion of the Board, all Independent Directors possess requisite qualifications, experience, expertise and hold high standards of integrity required to discharge their duties with an objective independent judgment and without any external influence.

14. STATEMENT REGARDING OPINION OF THE BOARD WITH REGARD TO INTEGRITY, EXPERTISE AND EXPERIENCE (INCLUDING THE PROFICIENCY) OF THE INDEPENDENT DIRECTORS APPOINTED DURING THE YEAR

The Company has 2 Independent Directors, Mr. Kewal Kundanlal Handa and Ms. Ekta Bahl and in the opinion of the Board, both of them possess requisite expertise, integrity and experience (including proficiency).

15. CORPORATE SOCIAL RESPONSIBILITY

The Company was required to spend CSR amount in FY 2023-24 and the Company is committed to taking up Corporate Social Responsibility activities. The Corporate Social Responsibility Report including brief details of CSR Policy is enclosed to this Board report as **Annexure II**.

16. RELATED PARTY TRANSACTIONS

During the year under the review, the Company entered only into related party transactions which were in the ordinary course of business and at arm's length basis.

The Particulars of contracts or arrangement with related parties referred under section 188 (1) of the Companies Act, 2013 and further, you are requested to refer Note No. 4.29 forming part of Balance Sheet for further details. There is also material related party transaction during the year details of the same are enclosed in **Annexure-I** in **Form AOC-2**.

17. PARTICULARS OF LOANS, GUARANTEES, AND INVESTMENTS MADE PURSUANT TO SECTION 186 OF THE COMPANIES ACT, 2013:

Particulars of loans given, investments made, guarantees given and securities provided along with the purpose for which the loan or guarantee or security is proposed to be utilized by the recipient are provided in the financial statements. Please refer to Notes of the Summary of significant accounting policies and other explanatory information.

18. STATEMENT OF RISK MANAGEMENT

The Company has adequate internal financial control system in place which operates effectively. According to the Directors of your Company, elements of risks that threaten the existence of your Company are very minimal. Hence, no separate Risk Management Policy is formulated.

19. EXTRACT OF ANNUAL RETURN

Pursuant to Section 92(3) read with Section 134(3)(a) of the Act, the Annual Return of the Company in Form MGT-7 for FY 2023-24, is available on the Company's website at <https://ciigmagroup.org/annual-reports/>

20. AUDITORS

20.1. STATUTORY AUDITOR

Members at their Twelfth Annual General Meeting held on 30th September, 2022 appointed M/s. Price Waterhouse Chartered Accountants LLP (FRN: 012754N/N500016), as Statutory Auditors of the Company for a period of 5 years till the conclusion of the Annual General Meeting to be held in 2027.

REPLY TO COMMENTS IN AUDITORS' REPORT

As required to be stated under section 134 (3)(f) of the Act, there are no qualifications, reservations or adverse remarks made by the Auditors in their independent auditor's report. The auditors' report and notes to accounts forming part of financial statements are self-explanatory and do not call for further explanation.

The Report given by the Auditors on the financial statements of the company is part of the Annual Report.

20.2. COST RECORD AND/OR COST AUDIT

Pursuant to Section 148 of the Companies Act, 2013, Company has appointed M/s. Nageswara Rao & Co, Cost Accountants as the Cost auditors for the Company for conducting the cost audit for the Financial Year 2023-24. The report does not contain any qualifications, reservations or adverse remarks or disclaimer.

The remuneration of the Cost Auditor as recommended by the Audit Committee and approved by the Board of Directors is required to be ratified subsequently by the Shareholders. Hence the resolution at Item no. 6 of the Notice of the Annual General Meeting (AGM) is recommended by the Board for members approval.

DISCLOSURE, AS TO WHETHER MAINTENANCE OF COST RECORDS

In accordance with the provisions of Section 148(1) of the Act, read with the Companies (Cost Records and Audit) Rules, 2014, the Company has maintained cost records.

20.3. SECRETARIAL AUDIT

The Board has appointed Rishabh J & associates, Practicing Company Secretaries for conducting the Secretarial Audit of the Company for the Financial year 2023-24 in accordance with the provisions of Section 204 of the Companies Act, 2013 and The Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

There are no qualifications, reservations or adverse remarks in the Secretarial Audit Report for the Financial Year 2023-24. The Secretarial Auditor's report is annexed as **Annexure III** and is a part of this report.

20.4. INTERNAL AUDIT

Internal audit function is adequately resourced commensurate with the operations of the Company. The provisions of section 138 of the Companies Act, 2013 read with Rule 13 of the Companies (Accounts) Rules, 2014 regarding appointment of internal auditor are applicable to the Company and as per the provisions the Board has appointed. Ernst & Young LLP, as Internal Auditors of the Company for conducting the internal audit for the financial year 2023-24.

21. DETAILS IN RESPECT OF FRAUDS REPORTED BY AUDITORS UNDER SUB-SECTION (12) OF SECTION 143 OTHER THAN THOSE WHICH ARE REPORTABLE TO THE CENTRAL GOVERNMENT

During the year under review, the statutory auditors have not reported any instances of fraud by its officers or employees against the Company to the Audit Committee, the details of which would need to be mentioned in the Board's report as required under section 143(12) of the Companies Act, 2013.

22. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO

The particulars relating to Conservation of Energy Technology, Absorption, Foreign Exchange Earnings and Outgo are as follows:

A. CONSERVATION OF ENERGY	
1. The steps taken or impact on conservation of energy.	<p>The company is making efforts to conserve energy through periodic monitoring and analysis of energy consumption.</p> <p>The Company has taken appropriate steps to reduce the consumption through timely maintenance/ installation/upgradation of all the energy consuming areas/equipment.</p> <p>The company has successfully implemented several energy conservation measures and is also working on renewable energy options like solar energy where, an approximate of 1.6 million units is being generated via solar PV annually, Heat pumps where the conservation initiatives has resulted in migration of traditional hot water generators using diesel fuel / conventional Geysers to Heat pump technology thus saving fossil fuel and hot water generation cost.</p> <p>Energy efficient air conditioning solutions like chillers, pumps and other associated measures have been implemented to optimize the energy savings and improve the patient service along with the ambience.</p> <p>All hospitals units have upgraded to LED lightings from conventional lighting systems.</p>
2. The steps taken by the Company for utilizing alternate sources of energy	

3. The Capital investment on energy conservation equipment	<p>As part of our water conservation efforts we have upgraded and refurbished the STP & RO systems across the group.</p> <p>All efforts have been taken in order to maintain the equipment in optimum working condition to increase the life span and to decrease the energy consumption without compromising the safety and comfort of patients and customers.</p>
B. TECHNOLOGY ABSORPTION	
1. The Efforts made towards technology absorption	<p>The company does not have in-house Research & Development department. However, the company continuously makes efforts towards sourcing medical & other equipment from vendors who adopt the latest state of art technology in their products/services. This endeavor ensures that the company always benefits in terms of cost reduction and improving efficiencies.</p> <p>Further the Company imported no technology during the year under review.</p>
2. The Benefits derived like product improvement, cost reduction, product development or import substitution	
3. Details of technology imported during the past 3 years	
4. The expenditure incurred on Research and Development	
C. FOREIGN EXCHANGE EARNINGS AND OUT GO	
Earning in foreign currency	NIL
Expenditure in foreign currency	NIL

23. DETAILS OF THE SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS/ COURTS/ TRIBUNALS IMPACTING THE GOING CONCERN STATUS AND THE COMPANY'S OPERATIONS IN FUTURE

During the year no significant and material orders were passed by the regulators / courts / tribunals impacting the going concern status and the company's operations in future.

24. VIGIL MECHANISM

Pursuant to section 177 (9) of Companies Act, 2013, the Company formulated Whistle Blower Policy.

The Whistle Blower Policy / Vigil Mechanism provides a mechanism for the Director / Employee to report violations without fear of victimisation of any unethical behaviour, suspected or actual fraud etc. which are detrimental to the organisation's interest. The mechanism protects whistle blower from any kind of discrimination, harassment, victimisation or any other unfair employment practice.

25. SECRETARIAL STANDARDS

The Company has complied with the applicable secretarial standards issued by the Institute of Company Secretaries of India on Board Meetings and General Meetings and approved by Central Government.

26. ADEQUACY OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO THE FINANCIAL STATEMENTS

The Company has well established policies and procedures for internal financial controls commensurate with its size and operations to safeguard and ensure prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets. All the transactions are properly authorized, recorded

and reported to the Management. The Company is following generally accepted accounting principles and Ind Accounting Standards for properly maintaining the books of accounts and reporting financial statements.

The Company continues to ensure proper and adequate systems and procedures commensurate with its size and nature of its business.

27. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013.

The Company has adopted a policy with the name “Policy on Prevention, Prohibition and Redressal of Sexual Harassment”. The policy is applicable for all employees of the organization, which includes corporate office, Units etc.

An Internal Committee has also been set up to redress complaints received on sexual harassment as required under the Sexual Harassment of Women at Workplace (Prevention, Prohibition & Redressal) Act, 2013.

Pursuant to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and Rules made thereunder, the information required to be disclosed under the provisions of the said Act are as follows:

Sr. No	Particulars	
(a)	number of complaints received during FY 2023-24	1
(b)	number of complaints disposed of during the FY 2023-24	1
(c)	number of cases pending for more than ninety days	0

28. THE DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 DURING THE YEAR. ALONG WITH THEIR STATUS AS AT THE END OF THE FINANCIAL YEAR

During the year under review, Operational creditor (Sentinel Capital) is private firm dealing in providing advisory services for companies looking in raise capital from third party investor since the services charges are not paid by CIIGMA, sentinel filed a under Insolvency and Bankruptcy case before NCLT- Mumbai.

United CIIGMA appeared in the said case and made representations to prove that Sentinel Capital does not entitle to receive any amount as claimed as no such services provided to the Company. Further the application filed under Section 9 of IBC, was rejected by the Hon'ble NCLT, Mumbai Bench, vide its order dated 20th August, 2024.

Except above no other case is pending.


29. DETAILS OF DIFFERENCE BETWEEN VALUATION REPORT ON ONE TIME SETTLEMENT AND VALUATION WHILE AVAILING LOAN FROM BANKS AND FINANCIAL INSTITUTIONS

During the year under review, the Company has not obtained any loans or any valuation report. Therefore, this clause is not applicable.

30. ACKNOWLEDGEMENT

Your Directors would like to express their sincere appreciation for the assistance and co-operation received from the Banks, Government authorities, Customers, Vendors and members during the year under review. Your Directors also wish to place on record their deep sense of appreciation for the committed services by the Company's executives, staff and workers.

For and on behalf of the Board of Directors
UNITED CIIGMA INSTITUTE OF MEDICAL SCIENCES PRIVATE LIMITED



Dr. Unmesh Vidyadhar Takalkar
Managing Director
DIN: 01578381
Date: 21-08-2024
Place: Aurangabad



Jasdeep Singh
Director
DIN: 02705303
Date: 21-08-2024
Place: Hyderabad

ANNEXURE-I

Form No. AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso thereto


1. Details of contracts or arrangements or transactions not at arm's length basis:

There are no contracts or arrangements or transactions which were not on arm's length basis

2. Details of material contracts or arrangement or transactions at arm's length basis:

Name(s) of the related party and nature of relationship	Nature of contracts/ arrangements/ transactions	Duration of the contracts / arrangements/ transactions	Salient terms of the contracts or arrangements or transactions including the value, if any	Date(s) of approval by the Board, if any	Amount paid as advances, if any
United CIIGMA Hospitals Healthcare Private Limited - Wholly Owned Subsidiary	Supply of Services	Continuing transaction	Supply of services provided to the Patient of UCHHPL for an amount of Rs. 4,29,99,205.64/- during the FY 2023-24.	May 29, 2024	NA
CIIGMA Institute of Medical Sciences Private Limited - Wholly Owned Subsidiary	Supply of Services	Continuing transaction	Supply of services provided to the Patient of CIMSPL for an amount of Rs. 6,59,192/- during the FY 2023-24	May 29, 2024	NA

**For and on behalf of the Board of Directors
UNITED CIIGMA INSTITUTE OF MEDICAL SCIENCES PRIVATE LIMITED**


Dr. Unmesh Vidyadhar Takalkar
Managing Director
DIN: 01578381
Date: 21-08-2024
Place: Aurangabad


Jasdeep Singh
Director
DIN: 02705303
Date: 21-08-2024
Place: Hyderabad

ANNEXURE-II

ANNUAL REPORT ON CSR ACTIVITIES

- 1. Brief outline on CSR Policy of the Company:** Corporate Social Responsibility (CSR) is the Company's commitment to its stakeholders to conduct business in an economically, socially and environmentally sustainable manner that is transparent and ethical.

The Company is committed to undertake CSR activities in accordance with the provisions of Section 135 of the Companies Act, 2013 read with relevant Rules.

The Company believes that corporate development has to be inclusive and every corporate has to be responsible for the development of a just and humane society that can build a national enterprise. The Company commits itself to contribute to the society in ways possible for the organization

AIMS & OBJECTIVES

- To develop a long-term vision and strategy for Company's CSR objectives.
- Establish relevance of potential CSR activities to Company's core business and create an overview of activities to be undertaken, in line with Schedule VII of the Companies Act, 2013.
- Company shall promote projects that are :
 - (a) Sustainable and create a long term change;
 - (b) Have specific and measurable goals in alignment with Company's philosophy;
 - (c) Address the most deserving cause or beneficiaries.
- To establish process and mechanism for the implementation and monitoring of the CSR activities for Company.

2. Composition of CSR Committee:

Pursuant to the provisions of Section 135(9) of the Companies Act, 2013, the CSR Committee has been dissolved w.e.f. 6th December, 2022.

*As per section 135(9) of The Companies act 2013 and rules made thereunder Where the amount to be spent by a company under Section 135 (5) does not exceed fifty lakh rupees, the requirement under Section 134(1) for constitution of the Corporate Social Responsibility Committee shall not be applicable and the functions of such Committee provided under this section shall, in such cases, be discharged by the Board of Directors of such company As a result, the CSR committee was not needed to be formed under Section 135(1) of the Companies Act 2013, and the meeting of the CSR committee was not convened due to non-applicability and the CSR Committee has been dissolved w.e.f. 6th December, 2022.

- 3.** Provide the web-link where Composition of CSR committee, CSR Policy and CSR projects approved by the board are disclosed on the website of the company. -<https://www.carehospitals.com/csr-policy>
- 4.** Provide the details of Impact assessment of CSR projects carried out in pursuance of sub-rule (3) of rule 8 of the Companies (Corporate Social responsibility Policy) Rules, 2014, if applicable (attach the report).
– **Not applicable**
- 5.** Details of the amount available for set off in pursuance of sub-rule (3) of rule 7 of the Companies (Corporate Social responsibility Policy) Rules, 2014 and amount required for set off for the financial year, if any –

6. Average net profit of the company as per section 135(5) – **Rs. 10,48,57,250/-**
7. (a) Two percent of average net profit of the company as per section 135(5) - **Rs. 20,97,145 /-**
(b) Surplus arising out of the CSR projects or programmes or activities of the previous financial years. – **Nil**
(c) Amount required to be set off for the financial year, if any – **9,690/-**
(d) Total CSR obligation for the financial year (7a+7b-7c) – **Rs. 20.87.455 /-**

Total Amount Spent for the Financial Year (in Rs.)	Amount Unspent (in Rs.)				
	Total Amount transferred to Unspent CSR Account as per section 135(6).		Amount transferred to any fund specified under Schedule VII as per second proviso to section 135(5).		
	Amount.	Date of transfer.	Name of the Fund	Amount.	Date of transfer.
Rs. 20,87,455/-	NA	NA	Nil	Nil	Nil

(1)	(2)	(3)	(4)	(5)		(6)	(7)	(8)	(9)	(10)	(11)	
Sl. No.	Name of the Project	Item from the list of activities in Schedule VII to the Act.	Local area (Yes/No).	Location of the project.		Project duration	Amount allocated for the project (in Rs.).	Amount spent in the current financial Year (in Rs.).	Amount transferred to Unspent CSR Account for the project as per Section 135(6) (in Rs.).	Mode of Implementation - Direct (Yes/No).	Mode of Implementation - Through Implementing Agency	
				State.	District.						Name	CSR Registration number.
Nil												

Sl. No.	Name of the Project	Item from the list of activities in schedule	Local area	Location of the project.	Amount spent for	Mode of implementation	Mode of implementation - Through implementing agency.
---------	---------------------	--	------------	--------------------------	------------------	------------------------	---

		VII to the Act.	(Yes/No).	State.	District.	the project (in Rs.).	- Direct (Yes/No)	Name.	CSR registration number.
1	Assetz Social Responsibility Association	Promoting education and awareness on health & hygiene	No	Telangana	Hyderabad	20,87,455/-	No	Assetz Social Responsibility Association	CSR00006492
Total						20,87,455/-			

- (d) Amount spent in Administrative Overheads- **Nil**
- (e) Amount spent on Impact Assessment, if applicable – **Not applicable**
- (f) Total amount spent for the Financial Year (8b+8c+8d+8e) - **Rs. 20,87,455/-**
- (g) Excess amount for set off, if any -

Sl. No.	Particular	Amount (in Rs.)
(i)	Two percent of average net profit of the Company as per section 135(5)	20,87,455.00
(ii)	Total amount spent for the Financial Year	20,87,455.00
(iii)	Excess amount spent for the financial year	Nil
(iv)	Surplus arising out of the CSR projects or programmes or activities of the previous financial years, if any	Nil
(v)	Amount available for set off in succeeding financial years [(iii)-(iv)]	Nil

9. (a) Details of Unspent CSR amount for the preceding three financial years: **Nil**

Sl. No.	Preceding Financial Year.	Amount transferred to Unspent CSR Account under section 135 (6) (in Rs.)	Amount spent in the Reporting Financial Year (in Rs.).	Amount transferred to any fund specified under Schedule VII as per section 135(6), if any.			Amount remaining to be spent in succeeding financial years. (in Rs.)
				Name of the Fund	Amount (in Rs.).	Date of transfer.	
Nil							

(b) Details of CSR amount spent in the financial year for **ongoing projects** of the preceding financial year(s):
NA

(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
Sl. No	Project ID.	Name of the Project	Financial Year in which the project was commenced	Project duration	Total amount allocated for the project (in Rs.).	Amount spent on the project in the reporting Financial Year (in Rs.).	Cumulative amount spent at the end of reporting Financial Year. (in Rs.)	Status of the project Completed/ Ongoing.
NIL								


- 10. In case of creation or acquisition of capital asset, furnish the details relating to the asset so created or acquired through CSR spent in the financial year - NA**

(Asset-wise details).

- Date of creation or acquisition of the capital asset(s).
- Amount of CSR spent for creation or acquisition of capital asset.
- Details of the entity or public authority or beneficiary under whose name such capital asset is registered, their address etc.
- Provide details of the capital asset(s) created or acquired (including complete address and location of the capital asset).

- 11. Specify the reason(s), if the company has failed to spend two per cent of the average net profit as per section 135(5). – NA**

For and on behalf of the Board of Directors
UNITED CIIGMA INSTITUTE OF MEDICAL SCIENCES PRIVATE LIMITED


Dr. Unmesh Vidyadhar Takalkar
Managing Director
DIN: 01578381
Date: 21-08-2024
Place: Aurangabad


Jasdeep Singh
Director
DIN: 02705303
Date: 21-08-2024
Place: Hyderabad



RISHABH J & ASSOCIATES

COMPANY SECRETARIES

8586874099
9557313935

Dated 21/08/24

FORM NO. MR-3

SECRETARIAL AUDIT REPORT FOR THE FINANCIAL YEAR ENDED 31.03.2024

[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,

The Members,

UNITED CIIGMA INSTITUTE OF MEDICAL SCIENCES PRIVATE LIMITED

CIN: U74120MH2011PTC213136

REGISTERED OFFICE: - PLOT NO. 6 & 7, SURVEY NO. 10, SHAHANOORWADI, DARGAH ROAD, AURANGABAD, MAHARASHTRA, 431005, INDIA.

We report that

We have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **UNITED CIIGMA INSTITUTE OF MEDICAL SCIENCES PRIVATE LIMITED** (hereinafter referred as '**the Company**'). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Company's Responsibilities

The Company's Management and Board of Directors are responsible for the maintenance of secretarial record under the Companies Act, 2013 and compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards. Further the Company's management and the Board of Directors are also responsible for establishing and maintaining adequate systems and process, commensurate with the size and operations of the company to identify, monitor and ensure compliances with the applicable laws, rules, regulations and guidelines.

Auditor's Responsibilities Statement

Our responsibility is only to examine and verify those compliances on a test basis and express an opinion on these secretarial records based on our audit.

We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.

We have not verified the correctness and appropriateness of financial records and Books of Accounts of the company. Where ever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.

The Secretarial Audit report is neither an assurance as to the future viability of the company nor



of the efficacy or effectiveness with which the management has conducted the affairs of the company.

Limitations

Due to the inherent limitations of an audit including internal, financial and operating controls, there is an unavoidable risk that some Misstatements or material non-compliances may not be detected, even though the audit is properly planned and performed in accordance with the Secretarial Auditing Standards as prescribed by Institute of Company Secretaries of India (ICSI).

Further, we conducted the secretarial audit by examining the secretarial records including minutes, documents, registers, other records and returns related to the applicable laws on the Company etc. The management has confirmed that the records submitted to us are the true and correct. We have also relied upon representation given by the management of the company for certain areas which otherwise requires physical verification.

Our Opinion & Basis

We have followed the audit practices; secretarial auditing standards and processes as were applicable and appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification in some cases were done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion. We also believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Report on Secretarial Records and Compliances thereof

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the Company has during the audit period covering the financial year ended on March 31, 2024 complied with the statutory provisions listed hereunder and also that the Company has proper Board- processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on March 31, 2024 according to the provisions of:

- (i) The Companies Act, 2013 (the Act) and the rules made thereunder;
- (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;
[Not Applicable]
- (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
- (iv) The Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;
- (v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):
 - (a) *The Securities and Exchange Board of India (Substantial Acquisition of Shares and



- Takeovers) Regulations, 2011;
- (b) *The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
 - (c) *The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;
 - (d) *The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;
 - (e) *The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014;
 - (f) *The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008;
 - (g) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;
 - (h) *The Securities and Exchange Board of India (Delisting of Equity shares) Regulations, 2009;
 - (i) *The Securities and Exchange Board of India (Buy back of Securities) Regulations, 2018.; -

*Not applicable

(vi) Other laws applicable specifically to the Company namely:

- (a) Employees' Provident Funds and Miscellaneous Provisions Act, 1952.
- (b) The Payment of Bonus Act, 1965
- (c) Employees' State Insurance Act, 1948
- (d) Maternity Benefit Act, 1961
- (e) Payment Of Gratuity Act, 1972

We have also examined compliance with the applicable provisions of the following: -

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India.
- (ii) The Listing Agreements entered into by the Company with the Stock Exchange(s); -

Not Applicable

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Standards and Guidelines etc. mentioned above.

Note: For clause (vi) above, the scope of our audit was limited to check the requisite licenses, permissions and registration under the specified Acts as provided by the management of the company. For the purpose of examining the adequacy of compliances with other applicable laws including industry/sector specific, under both Central and State legislations, reliance has been placed on the Compliance Certificate issued by the Management, on a quarterly basis, which were placed before the Board meeting, based on the reports received by the Company from various sites, along with action taken/to be taken, wherever required, as part of the Company's Compliance Management and Reporting System.



We further report that

The Board of Directors of the Company is duly constituted. The composition of the Board of Directors during the period under review were carried out in compliance with the provisions of the Act.


Adequate notice(s) has been given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance and in case of shorter notice, compliance as required under the Act has been made by the Company and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

All decisions at Board Meetings have been carried out with requisite majority of the members of the Board or unanimously. Further there is no case of views (if any) of the dissenting members as per the recordings in the minutes of the meetings of the Board.

We further report that there are adequate systems and process in the company commensurate with the size and operations of the company to monitor and ensure compliances with the applicable laws, rules, regulations and guidelines.

We further report that during the audit period, the company has not taken approval for any specific event/action having major bearing on the company's affairs in pursuance of the above referred laws, rules, regulations, standards & guidelines.

For Rishabh J & Associates
Company Secretaries



Rishabh Kumar Jain
Practicing Company Secretary

M. No. 65556

C.P. No. 24560

Peer Review No: - 3944/2023

UDIN: A065556F001125373

Date: 21/08/2024

Place: New Delhi

This Report is to be read with our letter of even date which is annexed as Annexure A and forms an integral part of this report.



RISHABH J & ASSOCIATES

COMPANY SECRETARIES

8586874099
9557313935

Dated 21/08/24

Annexure-A

To,

The Members,

UNITED CHIGMA INSTITUTE OF MEDICAL SCIENCES PRIVATE LIMITED

**REGISTERED OFFICE: - PLOT NO. 6 & 7, SURVEY NO. 10, SHAHANOORWADI,
DARGAH ROAD, AURANGABAD, MAHARASHTRA, 431005, INDIA**

Our report of even date is to be read along with this letter.

1. Maintenance of secretarial record is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and process as were appropriate to obtain reasonable assurance about the correctness of the contents of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the process and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. Where ever required, we have obtained the Management Representation about the Compliance of laws, rules and regulations and happening of events etc.
5. The Compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedure on test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

For Rishabh J & Associates
Company Secretaries

Rishabh Kumar Jain
Practicing Company Secretary

M. No. 65556

C.P. No. 24560

Peer Review No: - 3944/2023

UDIN: A065556F001125373

Date: 21/08/2024

Place: New Delhi

Office : 1/7271, G/F,
East Gorakh Park,
Shahdara, Delhi-110032
E-mail: csrishabhj@gmail.com

Price Waterhouse Chartered Accountants LLP

The Audit Committee
CC: Board of Directors

M/s. United Ciigma Institute of Medical Sciences Private Limited
Plot no. 6&7, Survey no. 10, Shahanoorwadi,
Dargah road, Aurangabad, Maharashtra – 431005

August 12, 2024

Dear Sirs,

Independence Discussions

We have been engaged to audit the financial statements of United Ciigma Institute of Medical Sciences Private Limited (“the Company”) for the year ending March 31, 2024. As the Statutory Auditors of the Company in India, we are required to follow Standard on Auditing (SA) 260 (Revised) - Communication with Those Charged with Governance. SA 260 requires that we communicate in writing with Those Charged with Governance regarding auditor independence.

Independence Discussions

We provide below an assessment and confirmation of our independence under the applicable Independence Rules.

In this regard we would be pleased to interact with the Audit Committee and Board of Directors to answer any questions on the matters covered by this letter.

Price Waterhouse & Affiliates Network of Firms registered as network with the Institute of Chartered Accountants of India comprises Lovelock & Lewes Chartered Accountants LLP (FRN 301056E /E300265), Lovelock & Lewes LLP (FRN 116150W/W100032), Price Waterhouse LLP (FRN 301112E /E300264), Price Waterhouse, Bangalore (FRN 007568S), Price Waterhouse & Co Bangalore LLP (FRN 007567S/S200012), Price Waterhouse & Co Chartered Accountants LLP (FRN 304026E/E300009), Price Waterhouse Chartered Accountants LLP (FRN 012754N/N500016), Price Waterhouse & Co (FRN 050032S), Dalal & Shah Chartered Accountants LLP (FRN 102020W/W100040), Choksey Bhargava & Co LLP (FRN 000059N/N500010) (collectively “PW&A Assurance Firms”) and Price Waterhouse & Co LLP (FRN 016844N/N500015) (together “Price Waterhouse & Affiliates”). Other Indian member firms within the PwC Network, operating in India that provide other than audit services to clients include PricewaterhouseCoopers Services LLP, PricewaterhouseCoopers Professional Services LLP, PwC Business Consulting Services LLP and PricewaterhouseCoopers Private Limited, having its subsidiary PricewaterhouseCoopers Bangladesh Private Limited in Bangladesh, (“PwCPL”), PwC Corporate Business Services LLP, PricewaterhouseCoopers Digital Services Private Limited and PricewaterhouseCoopers India LLP. Assurance and related services are rendered by PW&A Assurance Firms and tax and business advisory services are rendered by the firm Price Waterhouse & Co LLP (FRN 016844N/N 500015), PricewaterhouseCoopers Services LLP, PricewaterhouseCoopers Professional Services LLP, PwC Business Consulting Services LLP, PwCPL, PwC Corporate Business Services LLP, PricewaterhouseCoopers Digital Services Private Limited and, PricewaterhouseCoopers India LLP. Constituent of Price Waterhouse & Affiliates, PricewaterhouseCoopers Services LLP, PricewaterhouseCoopers Professional Services LLP, PwC Business Consulting Services LLP, PwCPL, PwC Corporate Business Services LLP, PricewaterhouseCoopers Digital Services Private Limited and PricewaterhouseCoopers India LLP are licensee member firms in India of the PricewaterhouseCoopers International Limited (“PwCIL”) that provide services to clients.



Price Waterhouse Chartered Accountants LLP, Unit - 2B, 8th Floor, Octave Block, Block E1, Parcel - 4, Salarpuria
Sattva Knowledge City, Raidurg, Hyderabad, Telangana - 500081
T: +91 (40) 4424 6000, F: +91 (40) 4424 6300

Registered office and Head office: 11-A, Vishnu Digamber Marg, Sucheta Bhawan, Gate No 2, 1st Floor, New Delhi - 110002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

Price Waterhouse Chartered Accountants LLP

Each member firm of the PwCIL network is independently owned and operates as a separate legal entity. PwCPL, PricewaterhouseCoopers Services LLP, PricewaterhouseCoopers Professional Services LLP, PwC Business Consulting Services LLP, PwC Corporate Business Services LLP, PricewaterhouseCoopers Digital Services Private Limited and PricewaterhouseCoopers India LLP are not “associate concerns” as defined in the Guidelines for members of the ICAI, Council Guidelines No.1- CA (7)/02/2008 dated August 8, 2008¹ of the Firms.

For the purposes of SA 260, independence is measured by each of the Firms individually in compliance with the following (“Independence rules”):

- a) Guidance Note on Independence of Auditors;
- b) The Code of Ethics, as issued by the ICAI, to ensure Independence of Auditors; The Chartered Accountants Act, 1949 (as amended); and The Chartered Accountants Regulations, 1988;
- c) The Companies Act, 2013 including Sections 141/144 as may be applicable; and
- d) Standards on Auditing, as may be applicable.

Under the above independence rules, we are not aware of any relationships between Price Waterhouse Chartered Accountants LLP (FRN no. 012754N/N500016) and the Company that, in our professional judgement, may reasonably be thought to bear on our independence which have occurred since July 31, 2023 the date of our last letter, through the date of this letter.

We report total fees to be charged during the year covered by the financial statements for audit and related services provided by Price Waterhouse Chartered Accountants LLP (FRN no. 012754N/N500016) to the Company:

Engagements	Fee (INR)
Statutory audit	600,000
Total	600,000

The above fees charged / chargeable do not include an element of contingent fees.

Outstanding Fees

There are no significant amounts of fees that have remained unpaid with respect to the professional services rendered by Price Waterhouse Chartered Accountants LLP (FRN no. 012754N/N500016) to the Company prior to the issuance of our audit report.

This letter is intended solely for the use of the Audit Committee, the Board of Directors, management, and others charged with governance within the Company and should not be used for any other purposes.

We look forward to discussing with you the matters addressed in this letter as well as other matters that may be of interest to you at the forthcoming Audit Committee meeting on August 21, 2024.

¹ the term “associate concern” means any corporate body or partnership firm, which renders the Management Consultancy and all other professional services permitted by the Council wherein the proprietor and/or partner(s) of the statutory auditor firm and/or their “relative(s)” is/are Director/s or partner/s and/or jointly or severally hold “substantial interest” in the said corporate body or partnership; (iii) the terms “relative” and “substantial interest” shall have the same meaning as are assigned thereto under Appendix (9) to the Chartered Accountants Regulations, 1988.



Price Waterhouse Chartered Accountants LLP

We will be prepared to answer any questions you may have regarding our independence as well as other matters.

We would ask the Audit Committee to take on record their assessment on the above matters with respect to the Independence rules as defined above.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016



Sudharmendra N
Partner
Membership Number: 223014

Place: Hyderabad
Date: August 12, 2024

Price Waterhouse Chartered Accountants LLP

Independent Auditor's Report

To the Members of United Ciigma Institute of Medical Sciences Private Limited

Report on the Audit of the Financial Statements

Opinion

1. We have audited the accompanying financial statements of United Ciigma Institute of Medical Sciences Private Limited ("the Company"), which comprise the Balance Sheet as at March 31, 2024, the Statement of Profit and Loss (including Other Comprehensive income/(loss)), the Statement of Changes in Equity and the Statement of Cash Flows for the year then ended, and notes to the financial statements, including material accounting policy information and other explanatory information.
2. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2024, total comprehensive income (comprising of profit and other comprehensive income), changes in equity and its cash flows for the year then ended.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information

4. The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Board's report, but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.



Price Waterhouse Chartered Accountants LLP, Unit - 2B, 8th Floor, Octave Block, Block E1, Parcel - 4, Salarpuria
Sattva Knowledge City, Raidurg, Hyderabad, Telangana - 500081
T: +91 (40) 4424 6000, F: +91 (40) 4424 6300

Registered office and Head office: 11-A, Vishnu Digamber Marg, Sucheta Bhawan, Gate No 2, 1st Floor, New Delhi - 110002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

Price Waterhouse Chartered Accountants LLP

INDEPENDENT AUDITOR'S REPORT

To the Members of United Ciigma Institute of Medical Sciences Private Limited
Report on Audit of the Financial Statements

Responsibilities of management and those charged with governance for the financial statements

5. The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.
6. In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's responsibilities for the audit of the financial statements

7. Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
8. As part of an audit in accordance with SAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
 - Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.



Price Waterhouse Chartered Accountants LLP

INDEPENDENT AUDITOR'S REPORT

To the Members of United Ciigma Institute of Medical Sciences Private Limited
Report on Audit of the Financial Statements

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
9. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on other legal and regulatory requirements

11. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of Section 143 of the Act, we give in the Annexure B a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
12. As required by Section 143(3) of the Act, we report that:
- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books, except for the matters stated in paragraph 12(h)(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 (as amended) ("the Rules"). Further, in the absence of sufficient appropriate audit evidence, we are unable to verify whether the backup of books of account and other books and papers maintained in electronic mode has been maintained on a daily basis on servers physically located in India during the year.
 - (c) The Balance Sheet, the Statement of Profit and Loss (including other comprehensive income/(loss)), the Statement of Changes in Equity and the Statement of Cash Flows dealt with by this Report are in agreement with the books of account.
 - (d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act.
 - (e) On the basis of the written representations received from the directors as on March 31, 2024, taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2024, from being appointed as a director in terms of Section 164(2) of the Act.
 - (f) With respect to the maintenance of accounts and other matters connected therewith, reference is made to our remarks in paragraph 12(b) above on reporting under Section 143(3)(b) and paragraph 12(h)(vi) below on reporting under Rule 11(g) of the Rules"
 - (g) With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A".
 - (h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company has disclosed the impact of pending litigations on its financial position in its financial statements – Refer Note 4.35 to the financial statements.



Price Waterhouse Chartered Accountants LLP

INDEPENDENT AUDITOR'S REPORT

To the Members of United Ciigma Institute of Medical Sciences Private Limited
Report on Audit of the Financial Statements

- ii. The Company was not required to recognise a provision as at March 31, 2024 under the applicable law or accounting standards, as it does not have any material foreseeable losses on long-term contract. The Company did not have any derivative contracts as at March 31, 2024.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company during the year ended March 31, 2024.
 - iv. (a) The management has represented that, to the best of its knowledge and belief, as disclosed in the Note 4.32(vii)(A) to the financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
 - (b) The management has represented that, to the best of its knowledge and belief, as disclosed in the Note 4.32(vii)(B) to the financial statements, no funds have been received by the Company from any person or entity, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
 - (c) Based on such audit procedures that we considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (a) and (b) contain any material misstatement.
 - v. The Company has not declared or paid any dividend during the year.
 - vi. Based on our examination, which included test checks, the accounting softwares used by the Company did not have a feature of audit trail (edit log) facility and, therefore, the question of our commenting on whether the audit trail had operated during the year or was tampered with, does not arise.
13. The Company has paid/ provided for managerial remuneration in accordance with the requisite approvals mandated by the provisions of Section 197 read with Schedule V to the Act.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016



Sudharmendra N
Partner
Membership Number: 223014

UDIN: 24223014BKHIHN9427

Place: Hyderabad
Date: August 21, 2024

Price Waterhouse Chartered Accountants LLP

Annexure A to Independent Auditor's Report

Referred to in paragraph 12(g) of the Independent Auditor's Report of even date to the members of United Ciigma Institute of Medical Sciences Private Limited on the financial statements for the year ended March 31, 2024

Report on the Internal Financial Controls with reference to Financial Statements under clause (i) of sub-section 3 of Section 143 of the Act

1. We have audited the internal financial controls with reference to financial statements of United Ciigma Institute of Medical Sciences Private Limited ("the Company") as of March 31, 2024 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

2. The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting ("the Guidance Note") issued by the Institute of Chartered Accountants of India ("ICAI"). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility

3. Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing deemed to be prescribed under Section 143(10) of the Act to the extent applicable to an audit of internal financial controls, both applicable to an audit of internal financial controls and both issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements was established and maintained and if such controls operated effectively in all material respects.
4. Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.
5. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system with reference to financial statements.



Price Waterhouse Chartered Accountants LLP

Annexure A to Independent Auditor's Report

Referred to in paragraph 12(g) of the Independent Auditor's Report of even date to the members of United Ciigma Institute of Medical Sciences Private Limited on the financial statements for the year ended March 31, 2024

Meaning of Internal Financial Controls with reference to financial statements

6. A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with reference to financial statements

7. Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

8. In our opinion, the Company has, in all material respects, an adequate internal financial controls system with reference to financial statements and such internal financial controls with reference to financial statements were operating effectively as at March 31, 2024, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note issued by ICAI.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016



Sudharmendra N
Partner
Membership Number: 223014
UDIN: 24223014BKHIHN9427

Place: Hyderabad
Date: August 21, 2024

Price Waterhouse Chartered Accountants LLP

Annexure B to Independent Auditors' Report

Referred to in paragraph 11 of the Independent Auditors' Report of even date to the members of United Ciigma Institute of Medical Sciences Private Limited on the financial statements as of and for the year ended March 31, 2024.

In terms of the information and explanations sought by us and furnished by the Company, and the books of account and records examined by us during the course of our audit, and to the best of our knowledge and belief, we report that:

- i. (a) (A) The Company is maintaining proper records showing full particulars, including quantitative details and situation, of Property, Plant and Equipment.

(B) The Company is maintaining proper records showing full particulars of Intangible Assets.
- (b) The Property, Plant and Equipment are physically verified by the Management according to a phased programme designed to cover all the items over a period of 3 years which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the programme, a portion of the Property, Plant and Equipment has been physically verified by the Management during the year and no material discrepancies have been noticed on such verification.
- (c) The title deeds of all the immovable properties as disclosed in Note 4.1 to the financial statements, are held in the name of the Company.
- (d) The Company has chosen cost model for its Property, Plant and Equipment and intangible assets. Consequently, the question of our commenting on whether the revaluation is based on the valuation by a Registered Valuer, or specifying the amount of change, if the change is 10% or more in the aggregate of the net carrying value of each class of Property, Plant and Equipment or intangible assets does not arise.
- (e) No proceedings have been initiated on (or) are pending against the Company for holding benami property under the Prohibition of Benami Property Transactions Act, 1988 (as amended in 2016) (formerly the Benami Transactions (Prohibition) Act, 1988 (45 of 1988)) and Rules made thereunder, and therefore the question of our commenting on whether the Company has appropriately disclosed the details in the financial statements does not arise.
- ii. (a) The physical verification of inventory has been conducted at reasonable intervals by the Management during the year and, in our opinion, the coverage and procedure of such verification by Management is appropriate. The discrepancies noticed on physical verification of inventory as compared to book records were not 10% or more in aggregate for each class of inventory.
- (b) During the year, the Company has been sanctioned working capital limits in excess of Rs. 5 crores, in aggregate, from banks on the basis of security of current assets. The Company has filed revised quarterly returns or statements with such banks which are in agreement with the unaudited books of account.
- iii. The Company has not made any investments, granted secured/ unsecured loans/advances in nature of loans, or stood guarantee, or provided security to any parties, except for loans provided in earlier years to its subsidiary Company. Therefore, the reporting under clause 3 (iii)(a), (iii)(b), and (iii)(f) of the Order are not applicable to the Company.
 - (a) In respect of the loans provided in earlier years, no schedule for repayment of principal and payment of interest has been stipulated by the Company. Therefore, in the absence of stipulation of repayment terms, we are unable to comment on the regularity of repayment of principal and payment of interest and whether there is any amount which is overdue for more than ninety days.



Price Waterhouse Chartered Accountants LLP

Annexure B to Independent Auditors' Report

Referred to in paragraph 11 of the Independent Auditors' Report of even date to the members of United Ciigma Institute of Medical Sciences Private Limited on the financial statements for the year ended March 31, 2024

- (b) There were no loans which have fallen due during the year and were renewed/extended. Further, no fresh loans were granted to same parties to settle the existing overdue loans.
- iv. The Company has not granted any loans or made any investments or provided any guarantees or security to the parties covered under Sections 185 and 186. Therefore, the reporting under clause 3(iv) of the Order are not applicable to the Company.
- v. The Company has not accepted any deposits or amounts which are deemed to be deposits referred in Sections 73, 74, 75 and 76 of the Act and the Rules framed there under.
- vi. Pursuant to the rules made by the Central Government of India, the Company is required to maintain cost records as specified under Section 148(1) of the Act in respect of its services. We have broadly reviewed the same and are of the opinion that, prima facie, the prescribed accounts and records have been made and maintained. We have not, however, made a detailed examination of the records with a view to determine whether they are accurate or complete.
- vii. (a) In our opinion, the Company is generally regular in depositing undisputed statutory dues in respect of provident fund, income tax and goods and services tax, though there has been a slight delay in a few cases, and is regular in depositing undisputed statutory dues, including employees' state insurance, sales tax, service tax, duty of customs, duty of excise, value added tax, cess and other material statutory dues, as applicable, with the appropriate authorities.
- (b) There are no statutory dues referred to in sub-clause (a) which have not been deposited on account of any dispute.
- viii. There are no transactions previously unrecorded in the books of account that have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.
- ix. (a) The Company has not defaulted in repayment of loans or other borrowings or in the payment of interest to any lender during the year.
- (b) We report that the Company has not been declared Wilful Defaulter by any bank or financial institution or government or any government authority.
- (c) The Company has not obtained any term loans during the year ended March 31, 2024 and there was no unutilized balance of term loan obtained in earlier years as on April 1, 2023. Accordingly, reporting under clause 3(ix)(c) of the Order is not applicable to the Company.
- (d) According to the information and explanations given to us, and the procedures performed by us, and on an overall examination of the financial statements of the Company, the Company has not raised funds on short-term basis. Accordingly, reporting under clause 3(ix)(d) of the Order is not applicable to the Company.
- (e) On an overall examination of the financial statements of the Company, we report that the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures.
- (f) We report that the Company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies.
- x. (a) The Company has not raised any money by way of initial public offer or further public offer (including debt instruments) during the year. Accordingly, the reporting under clause 3(x)(a) of the Order is not applicable to the Company.



Price Waterhouse Chartered Accountants LLP

Annexure B to Independent Auditors' Report

Referred to in paragraph 11 of the Independent Auditors' Report of even date to the members of United Ciigma Institute of Medical Sciences Private Limited on the financial statements for the year ended March 31, 2024

- (b) The Company has not made any preferential allotment or private placement of shares or fully or partially or optionally convertible debentures during the year. Accordingly, the reporting under clause 3(x)(b) of the Order is not applicable to the Company.
- xi. (a) During the course of our examination of the books and records of the Company, carried out in accordance with the generally accepted auditing practices in India, we have neither come across any instance of material fraud by the Company or on the Company, noticed or reported during the year, nor have we been informed of any such case by the Management.
- (b) During the course of our examination of the books and records of the Company, carried out in accordance with the generally accepted auditing practices in India, a report under Section 143(12) of the Act, in Form ADT-4, as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 was not required to be filed with the Central Government. Accordingly, the reporting under clause 3(xi)(b) of the Order is not applicable to the Company.
- (c) During the course of our examination of the books and records of the Company carried out in accordance with the generally accepted auditing practices in India, and as represented to us by the management, no whistle-blower complaints have been received during the year by the Company. Accordingly, the reporting under clause 3(xi)(c) of the Order is not applicable to the Company.
- xii. As the Company is not a Nidhi Company and the Nidhi Rules, 2014 are not applicable to it, the reporting under clause 3(xii) of the Order is not applicable to the Company.
- xiii. The Company has entered into transactions with related parties in compliance with the provisions of Sections 177 and 188 of the Act. The details of related party transactions have been disclosed in the financial statements as required under Indian Accounting Standard 24 "Related Party Disclosures" specified under Section 133 of the Act.
- xiv. (a) The internal audit of the Company is covered under the group internal audit pursuant to which an internal audit is carried out every year. In our opinion, the Company's internal audit system is commensurate with the size and nature of its business.
- (b) The reports of the Internal Auditor for the period under audit have been considered by us.
- xv. In our opinion, the Company has not entered into any non-cash transactions with its directors or persons connected with him. Accordingly, the reporting on compliance with the provisions of Section 192 of the Act under clause 3(xv) of the Order is not applicable to the Company.
- xvi. (a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, the reporting under clause 3(xvi)(a) of the Order is not applicable to the Company.
- (b) The Company has not conducted non-banking financial / housing finance activities during the year. Accordingly, the reporting under clause 3(xvi)(b) of the Order is not applicable to the Company.
- (c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, the reporting under clause 3(xvi)(c) of the Order is not applicable to the Company.




Price Waterhouse Chartered Accountants LLP

Annexure B to Independent Auditors' Report

Referred to in paragraph 11 of the Independent Auditors' Report of even date to the members of United Ciigma Institute of Medical Sciences Private Limited on the financial statements for the year ended March 31, 2024

- (d) Based on the information and explanations provided by the management of the Company, the Group (as defined in the Core Investment Companies (Reserve Bank) Directions, 2016) does not have any CICs, which are part of the Group. We have not, however, separately evaluated whether the information provided by the management is accurate and complete. Accordingly, the reporting under clause 3(xvi)(d) of the Order is not applicable to the Company.
- xvii. The Company has not incurred any cash losses in the financial year or in the immediately preceding financial year.
- xviii. There has been no resignation of the statutory auditors during the year and accordingly the reporting under clause 3(xviii) of the Order is not applicable.
- xix. On the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that the Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date will get discharged by the Company as and when they fall due.
- xx. As at balance sheet date, the Company does not have any amount remaining unspent under Section 135(5) of the Act. Accordingly, reporting under clause 3(xx) of the Order is not applicable.
- xxi. The reporting under clause 3(xxi) of the Order is not applicable in respect of audit of Standalone Financial Statements. Accordingly, no comment in respect of the said clause has been included in this report.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016


Sudharmendra N
Partner
Membership Number: 223014
UDIN: 24223014BKHIHN9427

Place: Hyderabad
Date: August 21, 2024

United Ciigma Institute of Medical Sciences Private Limited
Balance Sheet
(All amounts in ₹ millions, except share data and where otherwise stated)

Particulars	Notes	As at	As at
		31 March 2024	31 March 2023
ASSETS			
A. Non-current assets			
(a) Property, plant and equipment	4.1	1,684.98	1,709.66
(b) Intangible assets	4.2	5.08	-
(c) Financial assets			
(i) Investments	4.3	486.26	486.26
(ii) Other financial assets	4.4 (a)	239.98	264.78
(d) Deferred tax assets (net)	4.5	63.36	77.25
(e) Income tax asset (net)	4.6	38.36	47.84
(f) Other non-current assets	4.7 (a)	94.06	93.24
Total non-current assets (A)		2,612.08	2,679.03
B. Current assets			
(a) Inventories	4.8	19.30	23.02
(b) Financial assets			
(i) Trade receivables	4.9	224.32	172.53
(ii) Cash and cash equivalents	4.10 (a)	75.52	15.53
(iii) Bank balances other than (ii) above	4.10 (b)	81.00	68.26
(iv) Loans	4.11	0.09	0.13
(v) Other financial assets	4.4 (b)	32.77	32.89
(c) Other current assets	4.7 (b)	75.29	74.06
Total current assets (B)		508.29	386.42
Total assets (A+B)		3,120.37	3,065.45
EQUITY AND LIABILITIES			
Equity			
A. Equity			
(a) Equity share capital	4.12 (a)	513.67	513.67
(b) Other equity			
(i) Reserves and surplus	4.12 (b)	1,526.26	1,419.75
Total equity (A)		2,039.93	1,933.42
Liabilities			
B. Non-Current Liabilities			
(a) Financial liabilities			
(i) Borrowings	4.13	808.61	911.95
(b) Employee benefit obligations	4.14 (a)	0.62	0.77
Total non-current liabilities (B)		809.23	912.72
C. Current Liabilities			
(a) Financial liabilities			
(i) Borrowings	4.13	104.44	96.40
(ii) Trade payables	4.15		
(a) total outstanding dues of micro and small enterprises		51.19	-
(b) total outstanding dues other than (ii) (a) above		42.12	77.25
(iii) Other financial liabilities	4.16	65.31	41.70
(b) Employee benefit obligations	4.14 (b)	0.53	0.04
(c) Other current liabilities	4.17	7.62	3.92
Total current liabilities (C)		271.21	219.31
Total liabilities (B+C)		1,080.44	1,132.03
Total equity and liabilities (A+B+C)		3,120.37	3,065.45

The accompanying notes are an integral part of the financial statements.

This is the Balance Sheet referred to in our report of even date.

For **Price Waterhouse Chartered Accountants LLP**
Firm's Registration No: 012754N/N500016

Sudharmendra N
Partner
Membership No: 223014

Place: Hyderabad
Date: 21 August 2024

For and on behalf of Board of Directors of
United Ciigma Institute of Medical Sciences Private Limited
CIN - U74120MH2011PTC213136

Dr. Umesh Takalkar
Managing director
DIN - 01578381
Place: Aurangabad
Date: 21 August 2024

Anand Venugopal
Chief Financial Officer
PAN - AKHPV3361Q
Place: Hyderabad
Date: 21 August 2024

Jasdeep Singh
Director
DIN - 02705303
Place: Hyderabad
Date: 21 August 2024

Divyanki Sharma
Company Secretary
PAN - FSYPS3605A
Place: Hyderabad
Date: 21 August 2024


United Ciigma Institute of Medical Sciences Private Limited
Statement of Profit and Loss
(All amounts in ₹ millions, except share data and where otherwise stated)

Particulars	Notes	For the year ended	
		31 March 2024	31 March 2023
I Revenue from operations	4.18	1,392.76	1,237.04
II Other income	4.19	34.01	19.26
III Total income (I+II)		1,426.77	1,256.30
IV Expenses			
(i) Purchases of medical consumables, pharmacy items and other consumables		333.40	272.14
(ii) Changes in inventories of medical consumables, pharmacy items and other consumables	4.20	3.72	-
(iii) Employee benefits expense	4.21	46.72	45.98
(iv) Other expenses	4.22	689.58	576.73
Total expenses (IV)		1,073.42	894.85
V Earnings before interest, tax, depreciation and amortisation (EBITDA) (III-IV)		353.35	361.45
(i) Depreciation and amortisation expense	4.24	126.61	118.33
(ii) Finance costs	4.23	86.91	126.12
VI Profit before exceptional items and tax		139.83	117.00
Exceptional items	4.34	-	26.77
VII Profit before tax		139.83	90.23
VIII Income Tax expense/(credit):			
(i) Current tax expense	4.25	19.58	-
(ii) MAT Credit	4.25	(19.58)	-
(iii) Deferred tax expense	4.25	33.43	18.23
Total tax expense		33.43	18.23
IX Profit for the year (VII-VIII)		106.40	72.00
X Other comprehensive income/(loss):			
(i) Items that will not be reclassified to Statement of Profit and Loss			
(a) Remeasurement of post-employment benefit obligations		0.15	0.38
(ii) Income tax relating to these items		(0.04)	(0.10)
Other Comprehensive income for the year, net of tax		0.11	0.28
XI Total comprehensive income for the year (IX+X)		106.51	72.28
Earnings per equity share (Nominal value of equity share ₹10 (31 March 2023 : ₹10))			
Basic earnings per equity share (in ₹)	4.26	2.07	1.57
Diluted earnings per equity share (in ₹)		2.07	1.57

The accompanying notes are an integral part of the financial statements.


This is the Statement of Profit and Loss referred to in our report of even date.


For **Price Waterhouse Chartered Accountants LLP**
Firm's Registration No: 012754N/N500016



Sudharmendra N
Partner
Membership No: 223014


Place: Hyderabad
Date: 21 August 2024

For and on behalf of Board of Directors of
United Ciigma Institute of Medical Sciences Private Limited
CIN - U74120MH2011PTC213136


Dr. Umesh Takalkar
Managing director
DIN - 01578381
Place: Aurangabad
Date: 21 August 2024


Anand Venugopal
Chief Financial Officer
PAN - AKHPV3361Q
Place: Hyderabad


Jasdeep Singh
Director
DIN - 02705303
Place: Hyderabad
Date: 21 August 2024


Divyanki Sharma
Company Secretary
PAN - FSYP3605A
Place: Hyderabad

United Ciigma Institute of Medical Sciences Private Limited
Statement of Cash Flows
(All amounts in ₹ millions, except share data and where otherwise stated)

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Cash flow from operating activities		
Profit before income tax	139.83	90.23
Adjustments:		
Depreciation and amortisation expense	126.61	118.33
Expected credit loss	11.35	25.53
Loss on sale of Property, plant and equipment	16.66	-
Interest income	(33.60)	(17.79)
Finance costs	86.91	123.01
Change in operating assets and liabilities:	347.76	339.31
Decrease in inventories	3.72	26.77
(Increase) in trade receivables	(63.14)	(68.90)
Decrease in loans	0.04	0.33
(Increase)/decrease in other assets	(1.23)	224.36
(Increase) in other financial assets	(1.43)	(128.61)
Increase/(decrease) in trade payables	16.06	(21.74)
Increase in provisions	0.49	0.49
Increase in other financial liabilities	20.78	39.84
Increase/(decrease) in other liabilities	3.70	(4.53)
Cash generated from operations	326.75	407.32
Income tax paid, net	(10.10)	(116.81)
Net cash inflow from operating activities (A)	316.65	290.51
Cash flow from investing activities		
Payments for property, plant and equipment and intangible assets	(125.79)	(489.45)
Proceeds from sale of Property, plant and equipment	4.13	-
Interest received on fixed deposits	9.27	3.47
Interest received on income tax refund	2.31	1.58
Investment in subsidiaries	-	(486.26)
Investment in fixed deposits	(449.47)	(54.51)
Proceeds from maturity of fixed deposits	485.10	-
Net cash outflow from investing activities (B)	(74.45)	(1,025.17)
Cash flow from financing activities		
Repayments of long-term borrowings	(95.30)	(354.53)
Proceeds/(Repayments) from short term borrowings, net	-	(252.24)
Proceeds on issue of Equity Shares	-	1,418.75
Interest paid	(86.91)	(123.01)
Net cash (outflow)/inflow from financing activities (C)	(182.21)	688.97
Net increase/(decrease) in cash and cash equivalents(A + B + C)	59.99	(45.69)
Cash and cash equivalents at the beginning of the year	15.53	61.22
Cash and cash equivalents at the end of the year (note 1)	75.52	15.53
	For the period ended 31 March 2024	For the period ended 31 March 2023
Note 1:		
Cash and cash equivalents as per above comprise of the following		
- Included in cash and cash equivalents (refer note 4.10(a))		
Cash on hand	1.68	2.27
Balances with banks in current accounts	38.84	13.26
Deposits with maturity of less than three months	35.00	-
Balances as per Statement of Cash Flows	75.52	15.53

This is the Statement of Cash Flows referred to in our report of even date.

For **Price Waterhouse Chartered Accountants LLP**
Firm's Registration No: 012754N/N500016

Sudharmendra N
Partner
Membership No: 223014

Place: Hyderabad
Date: 21 August 2024

For and on behalf of Board of Directors of
United Ciigma Institute of Medical Sciences Private Limited
CIN - U74120MH2011PTC213136

Dr. Umesh Takalkar
Managing director
DIN - 01578381
Place: Aurangabad
Date: 21 August 2024

Anand Venugopal
Chief Financial Officer
PAN - AKHPV3361Q
Place: Hyderabad

Jasdeep Singh
Director
DIN - 02703303
Place: Hyderabad
Date: 21 August 2024

Divyanki Sharma
Company Secretary
PAN - FSYP3605A
Place: Hyderabad

United Ciiigma Institute of Medical Sciences Private Limited
Statement of Changes in Equity
(All amounts in ₹ millions, except share data and where otherwise stated)

A. Share capital

i) Equity share capital			
Particulars	Notes	Number of shares	Amount
Balance at 1 April 2022		35,000,000	350.00
Changes in equity share capital			
Balance as at 31 March 2023	4.12 (a)	16,366,711	163.67
Changes in equity share capital			
Balance as at 31 March 2024		51,366,711	513.67
			-
		51,366,711	513.67

B. Other equity

Particulars	Reserves and surplus		Total
	Securities premium	Retained earnings	
Balance at 1 April 2022	-	92.39	92.39
Profit for the year	-	72.00	72.00
Other comprehensive income, net of tax	-	0.28	0.28
Issue of equity shares at premium during the period	1,255.08	-	1,255.08
Balance at 31 March 2023	1,255.08	164.67	1,419.75
Profit for the year		106.40	106.40
Other comprehensive income, net of tax		0.11	0.11
Balance at 31 March 2024	1,255.08	271.18	1,526.26

The accompanying notes are an integral part of the financial statements.

This is the Statement of Changes in Equity referred to in our report of even date.

For Price Waterhouse Chartered Accountants LLP
Firm's Registration No: 012754N/NS00016

Sudharmendra N
Partner
Membership No: 223014

Place: Hyderabad
Date: 21 August 2024

For and on behalf of Board of Directors of
United Ciiigma Institute of Medical Sciences Private Limited
CIN - U74120MH2011PTC213136

Dr. Umesh Takalkar
Managing Director
DIN - 01578381
Place: Aurangabad
Date: 21 August 2024

Anand Venugopal
Chief Financial Officer
PAN - AKHPV3361Q
Place: Hyderabad
Date: 21 August 2024

Jasdeep Singh
Director
DIN - 02705303
Place: Hyderabad
Date: 21 August 2024

Divyanki Sharma
Company Secretary
PAN - FSYP3605A
Place: Hyderabad
Date: 21 August 2024

1. Company overview

United Ciigma Institute of Medical Sciences Private Limited (the “Company” or “UCIMSPL”) is headquartered in Aurangabad, India and was incorporated on 7th February, 2011 in accordance with the provisions of the erstwhile Companies Act, 1956. The Company is primarily engaged in providing healthcare and related services.

The Company has its registered office at Plot No. 6 & 7, Survey No. 10, Shahanoorwadi, Dargah Road, Aurangabad, Maharashtra - 431005, India.

The financial statements were authorised and approved for issue by the Company’s Board of Directors on 21 August 2024

The conditions prescribed under rule 6 of the Companies (Accounts) rules, 2014 have been satisfied for exemption of preparation of consolidated financial statements. Accordingly, the company has opted an exemption for preparation of consolidated financial statements.

2. Basis of preparation of the financial statements

2.1. Statement of Compliance

The financial statements of the Company have been prepared and presented in accordance with all the material aspects of the Indian Accounting Standards (Ind AS) as notified under Section 133 of the Companies Act, 2013 (the Act) read with the Companies (Indian Accounting Standards) Rules, 2015 and other relevant provisions of the Act. The Company has uniformly applied the accounting policies during the periods presented.

2.2. New amendments issued

The Ministry of Corporate Affairs vide notification dated 31 March 2023 notified the Companies (Indian Accounting Standards) Amendment Rules, 2023, which amended certain accounting standards (refer below), and are effective 1 April 2023:

- Disclosure of accounting policies - amendments to Ind AS 1
- Definition of accounting estimates - amendments to Ind AS 8
- Deferred tax related to assets and liabilities arising from a single transaction - amendments to Ind AS 12

The other amendments to Ind AS notified by these rules are primarily in the nature of clarifications.

These amendments did not have any material impact on the amounts recognised in prior periods and are not expected to significantly affect the current or future periods.

2.3. Functional and presentation currency

These financials statements are presented in Indian Rupees (₹), which is also the Company's functional currency. All amounts have been rounded-off to the nearest millions, unless otherwise indicated.

2.4. Basis for measurement

The financial statements have been prepared on the historical cost basis except for the following items:

Items	Measurement basis
Certain financial assets and liabilities	Fair value
Net defined benefit (asset)/liability	Fair value of present value of defined benefit obligations less fair value of plan assets

3 Use of estimates and judgments


The preparation of the financial statements in conformity with Ind AS requires the Management to make estimates, judgements and assumptions. These estimates, judgements and assumptions affect the application of accounting policies and the reported amounts of assets and liabilities, the disclosures of contingent liabilities at the date of the financial statements and reported amounts of revenues and expenses during the year. Application of accounting policies that require critical accounting estimates involving complex and subjective judgements and the use of assumptions in these financial statements have been disclosed. Accounting estimates could change from period to period. Actual results could differ from those estimates. Appropriate changes in estimates are made as the Management becomes aware of changes in circumstances surrounding the estimates. Changes in estimates are reflected in the financial statements in the period in which changes are made and, if material, their effects are disclosed in the notes to the financial statements.

Below are the areas involving critical estimates or judgements are:

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment in the year ended 31 March 2024 is included in the following notes:

- Useful lives of assets;
- Expected credit loss on financial assets;
- Contingencies

The material accounting policy information related to preparation of the financial statements have been discussed in the respective notes.



4.1 Property, plant and equipment

Accounting policy

Freehold land is carried at historical cost. All other property, plant and equipment is recognised at historical cost less depreciation less impairment loss if any. The Company has elected to adopt the carrying value of all of its property, plant and equipment recognised as of 1 April 2021 (transition date) measured as per the previous GAAP as its deemed cost as of transition date.

Depreciation methods and estimated useful lives

Depreciation is calculated using the straight-line method to allocate the cost of the assets, net of their residual values, over their estimated useful lives as follows:

Buildings	60 years
Medical and other equipments	13 years
Furniture and fixtures	10 years
Computer equipment	3 years

Particulars	Freehold land	Buildings	Medical and other equipments	Furniture and fixtures	Computer equipment	Total
Gross carrying amount						
Opening gross carrying amount as at 1 April 2022	-	675.22	522.89	238.42	35.95	1,472.48
Additions	415.93	2.81	59.37	9.82	1.52	489.45
Closing gross carrying amount as at 31 March 2023	415.93	678.03	582.26	248.24	37.47	1,961.93
Additions	-	2.51	106.90	2.06	11.24	122.71
Disposals	-	-	33.35	-	-	33.35
Closing gross carrying amount as at 31 March 2024	415.93	680.54	655.81	250.30	48.71	2,051.29
Accumulated Depreciation						
Opening accumulated depreciation as at 1 April 2022	-	11.90	58.38	29.76	33.90	133.94
Depreciation/other adjustments charge during the year	-	13.18	85.96	40.21	(21.02)	118.33
Closing accumulated depreciation as at 31 March 2023	-	25.08	144.34	69.97	12.88	252.27
Depreciation charge during the year	-	11.36	66.30	34.30	14.65	126.61
On disposals	-	-	12.57	-	-	12.57
Closing accumulated depreciation as at 31 March 2024	-	36.44	198.07	104.27	27.53	366.31
Net carrying amount as at 31 March 2023	415.93	652.95	437.92	178.27	24.59	1,709.66
Net carrying amount as at 31 March 2024	415.93	644.10	457.74	146.03	21.18	1,684.98

Note 1: The title deeds of all the immovable properties are held in the name of the Company.

Note 2: Refer note 4.13 for the details of property, plant and equipment pledged as security

Note 3: Refer note 4.35 for disclosure of contractual commitments for the acquisition of property, plant and equipment.

4.2 Intangible assets

Accounting policy

Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortisation and accumulated impairment losses. Intangible assets are amortised on straight line basis over the estimated useful economic life. The estimated useful life of intangible assets is 5 years.

Particulars	Software
Gross carrying amount	
Opening gross carrying amount as at 1 April 2022	-
Closing gross carrying amount as at 31 March 2023	-
Additions	5.08
Closing gross carrying amount as at 31 March 2024	5.08
Accumulated amortisation	
Closing accumulated amortisation as at 1 April 2022	-
Closing accumulated amortisation as at 31 March 2023	-
Amortisation charge for the year	*
Closing accumulated amortisation as at 31 March 2024	*
Closing net carrying amount as at 31 March 2023	-
Closing net carrying amount as at 31 March 2024	5.08

* below the rounding off norms adopted by the Company.



4.3 Investments

Accounting policy

The Company has accounted for its investments in subsidiaries at cost.

Particulars	As at 31 March 2024	As at 31 March 2023
Non-current		
Investment in equity instruments (fully paid up)		
Unquoted		
Investment in subsidiaries - at cost		
999,999 (31 March 2023: 999,999) equity shares in CIIGMA Institute of Medical Sciences Pvt Ltd	67.50	67.50
13,359,999 (31 March 2023: 13,359,999) equity shares in United CIIGMA Hospitals Healthcare Pvt Ltd*	418.76	418.76
Total	486.26	486.26

* includes deemed equity contribution of 259.86 (net of deferred tax of 91.30).

4.4 Other financial assets

Particulars	As at 31 March 2024	As at 31 March 2023
(a) Non current		
Unsecured, considered good		
Security deposits	7.16	4.89
Fixed deposits with banks with more than 12 months maturity*	47.43	95.80
Interest accrued on fixed deposits with banks	2.00	-
Interest free loan to subsidiary# (refer note 4.29)	183.39	164.09
Total	239.98	264.78
(b) Current		
Unsecured, considered good		
Advance to related party (refer note 4.29)	32.05	32.89
Interest accrued on fixed deposits with banks	0.72	-
Total	32.77	32.89

* Includes margin money held against bank guarantees of 0.8 (31 March 2023: 0.8).

Movement of interest free loan to subsidiary:

Particulars	As at 31 March 2024	As at 31 March 2023
Face value of interest free loan to subsidiary	502.51	502.51
Deemed equity contribution	(351.16)	(351.16)
Cumulative interest income	32.04	12.74
Interest free loan to subsidiary	183.39	164.09

Interest income is calculated by applying the effective interest rate of 12.75%. There are no repayment terms but the management has considered 10 years as tenure to recover based on the business plans.

4.5 Deferred tax assets/(liabilities), net


The following is the analysis of deferred tax assets/(liabilities), net recognised in the Statement of Profit and Loss and other comprehensive income

(i) Deferred tax assets/(liabilities) in relation to:	As at 1 April 2023	(Charged)/credited to Statement of Profit and Loss	(Charged)/credited to other comprehensive income	As at 31 March 2024
Property, plant and equipment ("PPE")	(101.09)	3.09	-	(98.00)
Expected credit loss	8.83	0.76	-	9.59
Provision for employee benefits	0.21	0.13	(0.04)	0.30
Deemed equity on account of interest free loan given to subsidiary	91.30	-	-	91.30
Interest on loan given to subsidiary	(3.31)	(5.02)	-	(8.33)
MAT credit	33.49	19.58	-	53.07
Unabsorbed depreciation and business losses	47.82	(32.60)	-	15.22
Provision for employee bonus	-	0.21	-	0.21
Total	77.25	(13.85)	(0.04)	63.36

(ii) Deferred tax assets/(liabilities) in relation to:	As at 1 April 2022	(Charged)/credited to Statement of Profit and Loss	(Charged)/credited to other comprehensive income	Recognised in investment in subsidiary	As at 31 March 2023
Property, plant and equipment ("PPE")	(108.46)	7.37	-	-	(101.09)
Expected credit loss	79.04	(70.21)	-	-	8.83
Provision for employee benefits	0.21	0.10	(0.10)	-	0.21
Deemed equity on account of interest free loan given to subsidiary	-	-	-	91.30	91.30
Interest on loan given to subsidiary	-	(3.31)	-	-	(3.31)
MAT credit	33.49	-	-	-	33.49
Unabsorbed depreciation and business losses	-	47.82	-	-	47.82
Total	4.28	(18.23)	(0.10)	91.30	77.25

Note:

The Company has recognised deferred tax asset on Unabsorbed depreciation and business losses. The management has concluded that such deferred tax asset will be recoverable using the estimated future taxable income based on approved business plans and budgets of the Company.



4.6 Income tax asset (net)

Particulars	As at 31 March 2024	As at 31 March 2023
Advance Tax (including TDS receivables)	57.94	47.84
Less:		
Provision for Income tax	(19.58)	-
Total	38.36	47.84

4.7 Other assets

Particulars	As at 31 March 2024	As at 31 March 2023
(a) Non-current		
Unsecured, considered good		
Capital advances	1.88	1.06
Other advances	92.18	92.18
Total	94.06	93.24

(b) Current

Unsecured, considered good		
Prepaid expenses	1.91	3.39
Other advances*	68.35	68.35
Advances to vendors	4.89	1.36
Others	0.14	0.96
Total	75.29	74.06

* Business transfer agreement entered on 13 July 2022 by and between Genesis IVF and Endoscopy Centre LLP (seller), United Ciigma Institute Medical Sciences Private Limited (purchaser) and Quality Care India Limited (investor) for transferring the business undertaking, including the ownership and operations on going concern basis, by way of slump sale for consideration as mutually agreed between the parties post satisfaction of certain conditions mentioned in the Business transfer agreement. The seller is still in the process of obtaining relevant approvals from the respective authorities to the transfer the business to purchaser, which is one of the conditions to the Business transfer agreement and hence the Business transfer is not effective as at year end. Management believes that the business transfer will occur within a year from the year end date.

has context menu

4.8 Inventories

Accounting policy

Inventory of medical consumables, pharmacy items and other consumables are valued at lower of cost or net realizable value. Cost of medical supplies, drugs and other consumables is determined on the basis of Weighted Average Method. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs necessary to make the sale.

Particulars	As at 31 March 2024	As at 31 March 2023
Medical consumables, pharmacy items and other consumables	19.30	23.02
Total	19.30	23.02

4.9 Trade receivables

Accounting policy

Trade receivables are amounts due from the customers for goods sold and services performed in the ordinary course of business and reflect the Company's unconditional right to consideration (that is, payment is due only on the passage of time).


Trade receivables are recognised initially at the transaction price as they do not contain significant financing components.

The Company follows 'simplified approach' for recognition of expected credit loss on trade receivables that do not contain a significant financing component.

The application of simplified approach does not require the Company to track changes in credit risk. Rather, it recognises expected credit loss based on lifetime expected credit loss (ECLs) at each reporting date, right from its initial recognition.

For trade receivables or any another financial asset that result from transactions that are within the scope of Ind AS 115, the Company always measures the loss allowance at an amount equal to the lifetime expected credit losses. Further, for the purpose of measuring lifetime expected credit loss allowance for these assets, the Company has used a practical expedient method as permitted under Ind AS 109. This expected credit loss allowance is computed based on a provision matrix which takes into account historical credit loss experience and adjusted for forward-looking information.

Particulars	As at 31 March 2024	As at 31 March 2023
Trade receivables from contract with customers – billed	250.57	187.60
Trade receivables from contract with customers – unbilled	10.63	10.46
Total	261.20	198.06
Less: Expected credit loss*	(36.88)	(25.53)
Total trade receivables and unbilled revenue	224.32	172.53
Trade receivables	213.97	162.35
Unbilled revenue	10.35	10.18



*The movement in the expected credit loss on trade receivables for the year ended 31 March 2024 and 31 March 2023 is as follows:

	As at 31 March 2024	As at 31 March 2023
Opening balance at beginning of the year	25.53	271.43
Provision made during the year (refer note 4.22)	11.35	25.53
Bad debts written off during the year	-	(271.43)
Closing balance at end of the year	36.88	25.53

Ageing of trade receivables and unbilled revenue as at 31 March 2024

Particulars	Unbilled	Not due	Outstanding for following periods from the due date				Total
			Less than 6 months	6 months - 1 year	1-2 years	More than 2 years	
Undisputed trade receivables							
-Considered good	10.63	159.94	32.75	22.54	35.34	-	261.20
-Expected credit loss rate	2.63%	9.99%	11.76%	18.46%	35.68%	-	
-Expected credit loss	(0.28)	(15.98)	(3.85)	(4.16)	(12.61)	-	(36.88)
Total	10.35	143.96	28.90	18.38	22.73	-	224.32

Ageing of trade receivables and unbilled revenue as at 31 March 2023

Particulars	Unbilled	Not due	Outstanding for following periods from the due date				Total
			Less than 6 months	6 months - 1 year	1-2 years	More than 2 years	
Undisputed trade receivables							
-Considered good	10.46	2.02	115.33	70.25	-	-	198.06
-Expected credit loss rate	2.68%	5.45%	8.63%	21.62%	-	-	-
-Expected credit loss	(0.28)	(0.11)	(9.95)	(15.19)	-	-	(25.53)
Total	10.18	1.91	105.38	55.06	-	-	172.53

4.10 Cash and bank balances

Particulars	As at 31 March 2024	As at 31 March 2023
a) Cash and cash equivalents		
Balances with banks		
-in current accounts	38.84	13.26
Cash on hand	1.68	2.27
Deposits with maturity of less than three months	35.00	-
	75.52	15.53
b) Other bank balances		
Deposits with maturity of more than 3 months but less than 12 months*	81.00	68.26
	81.00	68.26
Total	156.52	83.79

* Includes an amount of 26 (31 March 2023: 61) secured against the term loan with IndusInd Bank.

There are no repatriation restrictions with regard to cash and cash equivalents at the end of the reporting period and prior period.

4.11 Loans

Particulars	As at 31 March 2024	As at 31 March 2023
Unsecured, considered good		
Advances to employees	0.09	0.13
Total	0.09	0.13



4.12 (a) Equity share capital

Particulars	As at 31 March 2024	As at 31 March 2023
Authorised share capital		
52,000,000 Equity shares (31 March 2023: 50,000,000) of Rs.10/- each	520.00	520.00
Total authorised share capital	520.00	520.00
Issued, subscribed and fully paid up shares		
51,366,711 Equity Shares (31 March 2023: 51,366,711) of Rs. 10/- each	513.67	513.67
Total issued, subscribed and fully paid-up shares	513.67	513.67

Notes:

(i) Reconciliation of the shares outstanding at the beginning of the year and end of the reporting period

Equity Shares

Particulars	As at 31 March 2024		As at 31 March 2023	
	Number of shares	Amount	Number of shares	Amount
At the beginning of the year	51,366,711	513.67	35,000,000	350.00
Issued during the year	-	-	16,366,711	163.67
Balance at the end of the year	51,366,711	513.67	51,366,711	513.67

(ii) Rights, preferences and restrictions attached to equity shares

The Company has only one class of equity shares having par value of ₹10 per share. Each holder of equity shares is entitled to one vote per share. Where dividend is proposed by the Board of Directors, it is subject to the approval of the shareholders in the ensuing Annual General Meeting. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the company after distribution of all preferential amount. The distribution will be in proportion to the number of equity shares held by the shareholders.

(iii) Equity shares held by the Holding Company and Promoters

Particulars	As at 31 March 2024		As at 31 March 2023	
	Number of shares	Amount	Number of shares	Amount
Quality Care India Limited	39,040,870	390.41	39,040,870	390.41

(iv) Particulars of shareholders holding more than 5% equity shares

Particulars	As at 31 March 2024		As at 31 March 2023	
	Number of shares	% holding	Number of shares	% holding
Dr. Unmesh Vidyadhar Takalkar	11,873,941	23.12%	11,873,941	23.12%
Quality Care India Limited	39,040,870	76.00%	39,040,870	76.00%

(v) The Company has not bought back any equity shares during the period of five years immediately preceding the Balance Sheet date.

(vi) The Company has not issued any bonus shares or shares for consideration other than cash during the period of five years immediately preceding the last Balance Sheet date.



United Ciiigma Institute of Medical Sciences Private Limited

Notes to the financial statements

(All amounts in ₹ millions, except share data and where otherwise stated)

(vii) Details of shareholdings by the Promoter/Promoter Group

Promoter/Promoter Group Name	31 March 2024		31 March 2023	
	Number of Shares	% holding	Number of Shares	% holding
Dr. Unmesh Vidyadhar Takalkar	11,873,941	23.12%	11,873,941	23.12%
Dr. Manisha Unmesh Takalkar	92,000	0.18%	92,000	0.18%
Shweta Unmesh Takalkar	119,900	0.23%	119,900	0.23%
Total	12,085,841	23.53%	12,085,841	23.53%

4.12 (b) Other equity

Particulars	Reserves and surplus		Total
	Securities premium	Retained earnings	
Balance at 1 April 2022	-	92.39	92.39
Profit for the year	-	72.00	72.00
Other comprehensive income, net of tax	-	0.28	0.28
Issue of equity shares at premium during the period	1,255.08	-	1,255.08
Balance at 31 March 2023	1,255.08	164.67	1,419.75
Profit for the year	-	106.40	106.40
Other comprehensive income, net of tax	-	0.11	0.11
Balance at 31 March 2024	1,255.08	271.18	1,526.26

Nature and purpose of reserves

Securities premium

Securities premium is used to record the premium on issue of equity shares. It is utilised in accordance with provisions of the Companies Act, 2013 ("the Act").



United Ctiigma Institute of Medical Sciences Private Limited

Notes to the financial statements

(All amounts in ₹ millions, except share data and where otherwise stated)

4.13 Long-term borrowings

	As at 31 March 2024		As at 31 March 2023	
	Non-current	Current	Non-current	Current
Secured - at amortised cost				
Term loans from banks				
- IndusInd Bank- Term Loan - 1*	413.20	49.97	463.18	45.09
- IndusInd Bank- Term Loan - 3*	208.35	28.22	234.60	27.56
- The South Indian Bank Ltd#	187.06	26.25	214.17	23.75
Total	808.61	104.44	911.95	96.40

Notes:

Reconciliation of liabilities arising from financial activities excluding interest accrued

	For the year ended 31 March 2024	For the year ended 31 March 2023
Opening balance at beginning of the year	1,008.35	1,417.86
Repayments of borrowings	(95.30)	(409.51)
Closing balance at end of the year	<u>913.05</u>	<u>1,008.35</u>


Reconciliation of interest accrued on above borrowings

	For the year ended 31 March 2024	For the year ended 31 March 2023
Opening balance at beginning of the year	-	-
Interest expenses	86.91	123.01
Interest paid	(86.91)	(123.01)
Closing balance at end of the year	<u>-</u>	<u>-</u>

Note on Borrowings

* Secured by first and exclusive charge on all movable and current assets and collateral charge on hospital land and building. The loans are repayable in 6 to 8 years carries an interest rate of 9.36% p.a. (31 March 2023: 9.09% p.a) against term loan 1 and 8.35% p.a. (31 March 2023: 8.93% p.a) against term loan 3.

Secured by first and exclusive charge on all movable and current assets and collateral charge on hospital land and building. The loan is repayable in 7 years carries an interest rate of 8.56% (31 March 2023: 8.98% p.a.).



4.14 Employee benefit obligations

Particulars	As at 31 March 2024	As at 31 March 2023
(a) Non-current		
Gratuity	0.36	0.77
Compensated absences	0.26	-
Total	0.62	0.77
(b) Current		
Gratuity	0.26	0.04
Compensated absences	0.27	-
Total	0.53	0.04

4.15 Trade payables

Particulars	As at 31 March 2024	As at 31 March 2023
Trade payable : Micro and small enterprises	51.19	-
Trade payable : others	38.36	75.37
Trade payable to related parties (refer note 4.29)	3.76	1.88
Total	93.31	77.25

Ageing of trade payables as on 31 March 2024:

Particulars	Unbilled	Not due	Outstanding for following periods from the due date		Total
			Less than 1 year	More than 1 year	
Undisputed trade payables					
Micro and small enterprises	-	51.19	-	-	51.19
Others	5.27	35.06	1.79	-	42.12
Total	5.27	86.25	1.79	-	93.31

Ageing of trade payables as on 31 March 2023:

Particulars	Unbilled	Not due	Outstanding for following periods from the due date		Total
			Less than 1 year	More than 1 year	
Undisputed trade payables					
Micro and small enterprises	-	-	-	-	-
Others	7.03	49.55	20.67	-	77.25
Total	7.03	49.55	20.67	-	77.25

Details of dues to Micro and small enterprises are as follows

Particulars	As at 31 March 2024	As at 31 March 2023
i) The principal amount and the interest due thereon remaining unpaid to any supplier as at the end of the year.	51.19	-
ii) The amount of interest paid by the Company in terms of Section 16 of the MSMED Act, 2006 along with the amount of the payment made to the supplier beyond the appointed date during the year.	-	-
iii) The amount of the payments made to micro and small suppliers beyond the appointed day during each accounting	-	-
iv) The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under MSMED Act, 2006.	-	-
v) The amount of interest accrued and remaining unpaid at the end of each accounting year.	-	-
vi) The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise for the purposes of disallowance as a deductible expenditure under the MSMED Act, 2006.	-	-

Explanation.- The terms 'appointed day', 'buyer', 'enterprise', 'micro enterprise', 'small enterprise' and 'supplier', shall have the same meaning as assigned to them under clauses (b), (d), (e), (h), (m) and (n) respectively of section 2 of the Micro, Small and Medium Enterprises Development Act, 2006."



This information has been determined to the extent such parties have been identified on the basis of the information available with the Company.

4.16 Other financial liabilities

Particulars	As at 31 March 2024	As at 31 March 2023
Capital creditors	43.18	40.35
Employee benefit payables	4.98	1.28
Advance from related party (refer note 4.29)	17.08	-
Other payables	0.07	0.07
Total	65.31	41.70

4.17 Other liabilities

Particulars	As at 31 March 2024	As at 31 March 2023
Current		
Statutory dues payable	4.10	3.92
Unearned revenue	3.52	-
Total	7.62	3.92



4.18 Revenue from operations

Accounting policy:

Revenue from health care services and related activities

Income from healthcare services is recognised as revenue when the related services are rendered unless significant future uncertainties exists. Revenue is also recognised in relation to the services rendered, to the patients who are undergoing treatment/observation on the balance sheet date to the extent of services rendered. Revenue is recognised net of discounts and concessions, if any, given to the patients and disallowances.

Revenue from outpatient pharmacy

Revenue from sale of pharmacy is recognised when control is transferred to the customer and no significant uncertainty exists regarding the amount of the consideration that will be derived from the sale of the goods and regarding its collection.

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Revenue from healthcare services	1,294.84	1,093.29
Revenue from outpatient pharmacy	97.92	143.75
Total	1,392.76	1,237.04

Revenue disaggregation on geography wise is as follows:

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
India	1,392.76	1,237.04
	1,392.76	1,237.04

Reconciliation of contract price to revenue recognised from healthcare services is as follows:

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Contract price	1,313.28	1,101.70
Less: disallowances	(18.44)	(8.41)
Revenue from healthcare services	1,294.84	1,093.29

There are no disallowances in 'Revenue from outpatient pharmacy' during the current year and previous year.

4.19 Other income

Interest income is recorded using the effective interest rate (EIR).


Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
(a) Interest income		
On bank deposits	11.99	3.47
On income tax refund	2.31	1.58
On loan given to subsidiary	19.30	12.74
(b) Other non-operating income		
Miscellaneous income	0.41	1.47
Total	34.01	19.26

4.20 Changes in inventories of medical consumables, pharmacy items and other consumables

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Inventory at the beginning of the year	23.02	49.79
Inventory at the end of the year	19.30	23.02
Inventory written off	-	26.77
Total	3.72	-

4.21 Employee benefits expense

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Salaries, wages and bonus	43.66	43.25
Contribution to provident fund	1.81	1.87
Gratuity and compensated absences	0.99	0.48
Staff welfare expenses	0.26	0.38
Total	46.72	45.98



4.22 Other expenses

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Power and fuel	30.62	26.15
Repairs and Maintenance		
- Buildings	0.46	0.50
- Plant and machinery and others	29.77	26.96
Hospital maintenance	165.39	141.84
Insurance	4.74	5.88
Water charges	0.35	0.62
Rates and taxes	1.18	1.12
Travelling and conveyance	1.30	0.91
Communication expense	2.98	3.35
Marketing and business promotion expense	17.33	5.28
Expected credit loss	11.35	25.53
Printing and stationery	5.72	4.99
Payments to the auditor (note a)	0.60	0.60
Legal and professional charges	4.70	46.13
Catering charges	4.21	5.03
Diagnostics expenses	9.48	-
Contribution towards Corporate social responsibility (note b)	2.09	0.72
Professional charges to doctors	377.93	278.41
Loss on sale of Property, plant and equipment net	16.66	-
Bank charges	1.40	1.24
Miscellaneous expenditure	1.32	1.47
Total	689.58	576.73

Note (a): Details of payments to auditors

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
For statutory audit	0.60	0.60
	0.60	0.60

Note (b): Details of Corporate social responsibility


Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Contribution to ISKCON towards - Eradicating Hunger, poverty and malnutrition & Promoting Education and Skill development	-	0.72
Contribution to Assetz social responsibility association - towards Public awareness program, School support program, Upskilling & awareness on health & hygiene	2.09	-
Total	2.09	0.72

Details of CSR expenditure under Section 135(5) of the Act in respect of other than ongoing projects

Balance as at 1 April 2023	Amount deposited in specified fund of Schedule VII of the Act within 6 months	Amount required to be spent during the year	Amount spent during the year	Balance as at 31 March 2024
NIL	NIL	2.09	2.09	NIL

Details of CSR expenditure under Section 135(5) of the Act in respect of other than ongoing projects

Balance as at 1 April 2022	Amount deposited in specified fund of Schedule VII of the Act within 6 months	Amount required to be spent during the year	Amount spent during the year	Balance as at 31 March 2023
NIL	NIL	0.72	0.72	NIL



4.23 Finance costs

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2021
Interest on borrowings	86.91	123.01
Others	-	3.11
Total	86.91	126.12

4.24 Depreciation and amortisation expense

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2021
Depreciation on property, plant and equipment	126.61	118.33
Amortisation on intangible assets	*	-
Total	126.61	118.33

* below the rounding off norms adopted by the Company.

4.25 Income tax expense/ (credit)


Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Income tax expense/(credit) reported in the Statement of Profit and Loss		
Tax expense comprises of:		
Current tax expense	19.58	-
MAT Credit	(19.58)	-
Deferred tax expense	33.43	18.23
	33.43	18.23

Reconciliation of tax expense/ (credit) and the accounting profit multiplied by India's tax rate:

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Profit before tax	139.83	90.23
Tax at the Indian tax rate 26% (31 March 2023: 26%)	36.36	23.46
Tax effect of amounts which are not deductible/(taxable) in calculating taxable income:		
Impact of change in tax rate	-	(3.13)
Other adjustments	(2.93)	(2.10)
Tax expense	33.43	18.23

4.26 Earnings per equity share (EPES)

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Profit for the year	106.40	72.00
Number of equity shares outstanding at the beginning of the year	51,366,711	35,000,000
Add: Equity shares issued during the year	-	16,366,711
Total number of equity shares outstanding at the end of the year	51,366,711	51,366,711
Weighted average number of equity shares considered in computation of Basic EPES	51,366,711	45,911,141
Weighted average number of equity shares considered in computation of Dilutive EPES	51,366,711	45,911,141
Basic Earnings per equity share in ₹ (absolute number)	2.07	1.57
Diluted Earnings per equity share in ₹ (absolute number)	2.07	1.57



4.27 Segment Information

Based on the “management approach” as defined in Ind AS 108, Operating segments are to be reported in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker (CODM). The Company’s sole operating segment is therefore ‘Medical and Healthcare Services’. Accordingly, there are no additional disclosure to be provided under Ind AS 108, other than those already provided in the financial statements. Further the business operation of the Company are concentrated in India, and hence, the Company is considered to operate only in one geographical segment.

4.28 Employee benefits

Defined benefit plan

The Company operates post-employment defined benefit plan that provide gratuity. The gratuity plan entitles an employee, who has rendered at least five years of continuous services, to receive one-half month's last drawn salary for each year of completed services at the time of retirement/exit. The scheme is managed by Life Insurance Corporation of India. The Company's obligation in respect of gratuity plan, which is a defined benefit plan is provided for based on actuarial valuation carried out by an independent actuary using the projected unit credit method. The Company recognizes actuarial gains and loss immediately in the Statement of Profit and Loss. The Company accrues gratuity as per the provisions of the payment of Gratuity Act,1972 as applicable as at the balance sheet date.

A Based on the actuarial valuation obtained in this respect, the following table sets out the status of the gratuity plan and the amounts recognised in the Company's financial statements as at the balance sheet date:

Particulars	As at 31 March 2024	As at 31 March 2023
Defined benefit obligations	1.13	0.81
Fair value of plan assets	0.51	-
Net defined benefit liability	0.62	0.81
Total employee benefit liability	0.62	0.81
Non-current	0.36	0.77
Current	0.26	0.04

B Reconciliation of net defined benefit obligation

The following table shows a reconciliation from the opening balances to the closing balances for net defined benefit obligation and its components.

i) Reconciliation of present value of defined benefit obligation

Particulars	As at 31 March 2024	As at 31 March 2023
Defined benefit obligation at the beginning of the year	0.81	0.70
Current service cost	0.41	0.43
Interest expense	0.06	0.06
Actuarial (gains)/losses recognised in other comprehensive income		
- changes in Demographic assumptions	(0.49)	-
- changes in financial assumptions	-	(0.03)
- experience adjustments	0.34	(0.35)
Defined benefit obligation as at the balance sheet date	1.13	0.81

ii) Reconciliation to fair value of plan assets

Particulars	As at 31 March 2024	As at 31 March 2023
Plan assets at beginning of the year	-	-
Contributions paid	0.49	-
Interest income	0.02	-
Plan assets at end of the year	0.51	-



C (i) Expenses recognised in Statement of Profit and Loss

Particulars	As at 31 March 2024	As at 31 March 2023
Current service cost	0.41	0.43
Interest on net defined liability/ (asset)	0.04	0.06
Net cost, included in employee benefits expense	0.45	0.49

(ii) Remeasurements recognised in other comprehensive income (OCI)

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Actuarial (gain) / loss on defined benefit obligation	(0.15)	(0.38)
Closing amount recognised in OCI outside Statement of Profit and Loss	(0.15)	(0.38)

D Plan assets

Plan assets comprises of the following:

Particulars	As at 31 March 2024	As at 31 March 2023
Fund managed by Insurer	0.51	-

E Other disclosures

i) Actuarial assumptions

The following are the principal actuarial assumptions at the reporting date (expressed as weighted averages):

Principal actuarial assumptions	As at 31 March 2024	As at 31 March 2023
Attrition rate	40.00%	5.00%
Discount rate	7.23%	7.52%
Salary escalation rate	5.00%	5.00%
Retirement age	58 years	58 years

Maturity profile of defined benefit obligation

Particulars	As at 31 March 2024	As at 31 March 2023
Year 1	0.81	0.04
Year 2 to 5	0.28	0.26
Year 6 to 10	0.18	0.42
For 11 years and above	0.05	1.06

Sensitivity analysis

The change in the present value of defined benefit obligation for a change of 100 basis points from the assumed assumption is given below:



Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Salary escalation (+ 1% movement)	1.16	0.87
Salary escalation (- 1% movement)	(1.11)	(0.74)
Discount rate (+ 1% movement)	(1.12)	(0.74)
Discount rate (- 1% movement)	1.15	0.88

The Company's expected contribution for defined benefit obligation during the next year is 0.62 (31 March 2023: nil)

F Defined contribution plan

The Company's contribution towards its provident fund is a defined contribution retirement plan for qualifying employees. The Company's contribution to the Employees Provident Fund is deposited with Provident Fund Commissioner which is recognised by the Income Tax authorities. Details for the expenditure recognised in the Statement of Profit and Loss is as below:

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Amount recognised in the Statement of Profit and Loss towards Provident fund contributions	1.81	1.87



4.29 Related party transactions

(a) Parties where control exists or where significant influence exists and with whom transactions have taken place during the current year or previous year

List of Parties

Relation

Director
Director
Director
Director
Managing Director
Director
Independent Director
Independent Director
Key managerial personnel
Key managerial personnel

Key Managerial Personnel

Mr. Jasdeep Singh
Mr. Vikas Rastogi (till 17th November 2023)
Mr. Tejas Deepak Naphade (from 17th November 2023)
Mr. Mahadevan Narayanamoni (from 17th November 2023)
Dr. Unmesh Takalkar
Dr. Manisha Takalkar
Mr. Kewal Kundanlal Handa
Mrs. Ekta Bahl
Mr. Anand Venugopal, CFO (w.e.f 25th November 2023)
Mrs. Divyanki Sharma, Company Secretary (w.e.f 01st January 2024)

Relation

Ultimate Holding Company
Ultimate Holding Company
Holding Company
Subsidiary
Subsidiary
Entities in which KMPs are interested/significant influence.

Holding Company/Subsidiaries/Associates

TPG Capital, L.P. (till 26 October 2023)
BCP Asia II Holdco IV Pte. Ltd (w.e.f. 27 October 2023)
Quality Care India Limited (w.e.f. 26 July 2022)
Ciigma Institute of Medical Sciences Private Limited
United Ciigma Hospitals Healthcare Private Limited
Genesis IVF & Endoscopy Centre LLP


(b) The schedule of related party transactions are as follows

Transaction details	For the year ended 31 March 2024	For the year ended 31 March 2023
Transactions during the year		
i) Dr. Unmesh Takalkar		
a) Professional Fees	60.71	39.60
b) Managerial Remuneration	4.65	2.40
c) Purchase of Hospital Plot	-	415.93
d) Sale of Medicines	0.07	-
ii) Dr. Manisha Takalkar		
a) Purchase of Shares- United Ciigma Hospitals Healthcare Private Limited	-	47.60
iii) Mr. Kewal Kundanlal Handa		
a) Director sitting fees	3.75	-
iv) Mrs. Ekta Bahl		
a) Director sitting fees	3.75	-
iii) Ciigma Institute of Medical Sciences Private Limited		
a) Income from Lab testing services	-	2.35
b) Other Advances given	0.66	-
c) Other Advances taken	0.70	2.10
iv) United Ciigma Hospitals Healthcare Private Limited		
a) Loan given	-	472.09
b) Other Advances given	26.28	11.20
c) Other Advances taken	43.36	-
v) Convenient Hospitals Limited		
a) Purchase of Capital Goods	4.50	-

(c) Balances receivable/(payable)

Transaction details	As at 31 March 2024	As at 31 March 2023
Balances outstanding from/ to the related parties		
i) Advance to related party		
a) Ciigma Institute of Medical Sciences Private Limited	31.45	32.89
b) Genesis IVF & Endoscopy Centre LLP	0.60	0.60
ii) Advance from related party		
a) United Ciigma Hospitals Healthcare Private Limited	(17.08)	-
iii) Interest free loan to subsidiary		
a) United Ciigma Hospitals Healthcare Private Limited*	502.51	502.51
iv) Other receivables		
a) United Ciigma Hospitals Healthcare Private Limited	-	11.84
v) Other Advances		
a) Genesis IVF & Endoscopy Centre LLP	68.35	68.35
vi) Trade payables		
Dr. Unmesh Takalkar	(3.76)	(1.88)

* Represents undiscounted receivables



United Ciigma Institute of Medical Sciences Private Limited**Notes to the financial statements**

(All amounts in ₹ millions, except share data and where otherwise stated)

4.30 Capital risk management

For the purpose of the Company's capital management, capital includes issued equity capital, share premium and all other equity reserves attributable to the equity holders. The primary objective of the capital management is to maximise the shareholder value. The Company manages its capital structure and makes adjustments in light of changes in economic conditions and the requirements of the financial covenants. To maintain or adjust the capital structure, the Company may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The Company monitors capital using a gearing ratio, which is net debt divided by total equity plus net debt. The Company includes within net debt, borrowings (long and short term), less cash and cash equivalents.

Particulars	As at 31 March 2024	As at 31 March 2023
Borrowings	913.05	1,008.35
Less: Cash and cash equivalents and other bank balances	(156.52)	(83.79)
Net debt	756.53	924.56
Total equity	2,039.93	1,933.42
Capital and net debt	2,796.46	2,857.98
Gearing ratio (%)	27.05%	32.35%

In order to achieve this overall objective, the Company's capital management, amongst other things, aims to ensure that it meets financial covenants attached to the borrowings. Breaches in meeting the financial covenants would permit the lenders to immediately call back the borrowings. There have been no breaches in the material financial covenants of any borrowings in the current year. No changes were made in the objectives, policies or processes for managing capital during the year ended 31 March 2024.


4.31 Financial instruments**i) Categories of financial instruments**

	As at 31 March 2024	As at 31 March 2023
Financial assets		
Measured at amortised cost		
Other financial assets	272.75	297.67
Trade receivables	224.32	172.53
Cash and cash equivalents	75.52	15.53
Bank balances other than above	81.00	68.26
Loans	0.09	0.13
Total	653.68	554.12

	As at 31 March 2024	As at 31 March 2023
Financial liabilities		
Measured at amortised cost		
Trade payables	93.31	77.25
Borrowings	913.05	1,008.35
Other financial liabilities	65.31	41.70
Total	1,071.67	1,127.30

The carrying amount of financial assets and financial liabilities measured at amortised cost in the financial statements are a reasonable approximation of their fair values since the Company does not anticipate that the carrying amounts would be significantly different from the values that would eventually be received or settled.

The fair value of all the Financial assets and financial liabilities of the Company are measured at level 3.



ii) Financial risk management

The Company's activities expose it to a variety of financial risks: credit risk, liquidity risk and market risk.

a) Risk management framework

The Company's Board of Directors have overall responsibility for the establishment and oversight of the Company's risk management framework. The Board of Directors has established the risk and compliance committee, which is responsible for developing and monitoring the Company's risk management policies. The committee reports regularly to the Board of Directors on its activities.

The Company's principal financial liabilities, comprises of borrowings, trade and other payables and other financial liabilities. The main purpose of these financial liabilities is to finance the Company's operations. The Company's principal financial assets include loans, trade and other receivables, cash and bank balances and other financial assets that the Company derives directly from its operations. The Company is exposed primarily to Credit Risk, Liquidity Risk and Market risk (fluctuations in interest rates), which may adversely impact the fair value of its financial instruments. The Company assesses the unpredictability of the financial environment and seeks to mitigate potential adverse effects on the financial performance of the Company.

b) Credit Risk

Credit risk is the risk that counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. Credit risk encompasses of both, the direct risk of default and the risk of deterioration of creditworthiness as well as concentration of risks. Credit risk arises primarily from financial assets such as trade receivables, other balances with banks, loans and other receivables.

Credit risk is controlled by analysing credit limits and creditworthiness of customers on a continuous basis to whom the credit has been granted after obtaining necessary approvals for credit. Financial instruments that are subject to concentrations of credit risk principally consist of trade receivables, cash and cash equivalents, bank deposits and other financial assets.

Financial assets that are neither past due nor impaired

Ind AS requires expected credit losses to be measured through a loss allowance. The Company assesses at each Balance Sheet date whether a financial asset or a group of financial assets are impaired. Expected credit losses are measured at an amount equal to the life time expected credit losses. The Company has used a practical expedient by computing the expected credit loss allowance for trade receivables based on a provision matrix. The provision matrix takes into account historical credit loss experience and adjusted for forward looking information.

None of the Company's cash and cash equivalents, including fixed deposits, were either past due or impaired as at 31 March 2024. Credit risk on cash and cash equivalents, including fixed deposits is limited as the Company generally transacts with banks and financial institutions with high credit ratings assigned by international and domestic credit rating agencies.


No single customer accounted for more than 10% of the revenue as of 31 March 2024 and 31 March 2023. There is no significant concentration of credit risk.

c) Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation.

The table below provides details regarding the undiscounted contractual maturities of significant financial liabilities as of 31 March 2024:

Particulars	Less than 1 year	1-5 years	More than 5 years	Total
Borrowings	104.44	625.37	183.24	913.05
Trade payables	93.31	-	-	93.31
Other financial liabilities	65.31	-	-	65.31
Total	263.06	625.37	183.24	1,071.67



United Ciigma Institute of Medical Sciences Private Limited**Notes to the financial statements**

(All amounts in ₹ millions, except share data and where otherwise stated)

The table below provides details regarding the undiscounted contractual maturities of significant financial liabilities as of 31 March 2023:

Particulars	Less than 1 year	1-5 years	More than 5 years	Total
Borrowings	94.44	629.98	283.93	1,008.35
Trade payables	77.25	-	-	77.25
Other financial liabilities	41.70	-	-	41.70
Total	213.39	629.98	283.93	1,127.30

d) Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Considering the nature of the Company's financial instruments, the Company is exposed to interest rate risk.

e) Interest rate risk exposure

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's investments in deposits are with banks and reputed financial institutions and therefore do not expose the Company to significant interest rates risk.

The exposure of the Company's financial assets and financial liabilities on interest rate changes at the end of the reporting period are as follows:

Particulars	As at 31 March 2024	As at 31 March 2023
Fixed rate instruments		
Financial assets		
Fixed deposits	163.43	164.06
Variable rate instruments		
Financial liabilities		
Borrowings	913.05	1,008.35

Sensitivity analysis

Particulars	Impact on Statement of Profit and Loss	
	As at 31 March 2024	As at 31 March 2023
1% increase in MCLR	9.13	10.08
1% decrease in MCLR	(9.13)	(10.08)



4.32 Additional regulatory information required by Schedule III

- (i) **Details of benami property held**
No proceedings have been initiated on or are pending against the company for holding benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and Rules made thereunder.
- (ii) **Borrowing secured against current assets**
The company has borrowings from banks and financial institutions on the basis of security of current assets. The revised quarterly returns or statements of current assets filed by the company with banks and financial institutions are in agreement with the books of accounts.
- (iii) **Wilful defaulter**
The company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.
- (iv) **Relationship with struck off companies**
The company has no transactions with the companies struck off under Companies Act, 2013 or Companies Act, 1956.
- (v) **Compliance with number of layers of companies**
The company has complied with the number of layers prescribed under the Companies Act, 2013.
- (vi) **Compliance with approved scheme(s) of arrangements**
The company has not entered into any scheme of arrangement which has an accounting impact on current or previous financial year.
- (vii) **Utilisation of borrowed funds and share premium**
(A) The company has not advanced or loaned or invested funds to any other persons or entities, including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
a. directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or
b. provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries.
(B) The company has not received any fund from any persons or entities, including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the company shall:
a. directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
b. provide any guarantee, security or the like on behalf of the ultimate beneficiaries.
- (viii) **Undisclosed income**
There is no income surrendered or disclosed as income during the current or previous year in the tax assessments under the Income Tax Act, 1961, that has not been recorded in the books of account.
- (ix) **Details of crypto currency or virtual currency**
The company has not traded or invested in crypto currency or virtual currency during the current or previous year.
- (x) **Valuation of Property, plant and equipment, intangible asset and investment property**
The company has not revalued its property, plant and equipment or intangible assets or both during the current or previous year.

4.33 Other regulatory information

- (i) **Title deeds of immovable properties not held in name of the company**
The title deeds of all the immovable properties are held in the name of the company.
- (ii) **Registration of charges or satisfaction with Registrar of Company:**
There are no charges or satisfaction which are yet to be registered with the Registrar of Companies beyond the statutory period.
- (iii) **Utilisation of borrowings availed from banks and financial institutions**
The Company has not obtained borrowings from banks and financial institutions during the year.

4.34 In previous year, post the acquisition of the Company by Quality Care India Limited on 26 July 2022, the management has determined, based on their physical verification of inventory representing medical consumables and pharmacy items, as not fit for consumption. Hence, the management has charged off the inventory amounting to 26.77 to the Statement of Profit and Loss as an exceptional item.

4.35 Contingent liabilities and commitments

Accounting policy

Contingent liability is disclosed in the case of:

- a present obligation arising from past events, when it is not probable that an outflow of resources will be required to settle the obligation;
- a present obligation arising from past events, when no reliable estimate possible;
- a possible obligation that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity.

Significant Estimate : Management uses single most likely outcome for estimating the financial impact from litigations. Based on judicial pronouncements in similar cases or from opinions obtained from internal/ external legal counsel, management arrives at the possible outcome of the litigation.


Contingent liabilities

Particulars	As at 31 March 2024	As at 31 March 2023
Legal claims from third party	189.38	-

In respect of above matters, future cash outflows in respect of contingent liabilities are determinable only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company.

Capital Commitments

Particulars	As at 31 March 2024	As at 31 March 2023
Estimated amount of contracts remaining to be executed on capital account and not provided for (net of advances)	14.03	-



United Ciigma Institute of Medical Sciences Private Limited

(All amounts are in ₹ millions, unless otherwise stated)

4.36 Summary of other accounting policies

This note provides a list of other accounting policies adopted in the preparation of these financial statements to the extent they have not already been disclosed in the other notes. These policies have been consistently applied to all the years presented, unless otherwise stated.

A) Current and non-current classification

All the assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set out in the Schedule III to the Act.

Assets:

An asset is classified as current when it satisfies any of the following criteria:

- a) it is expected to be realized in, or is intended for sale or consumption in, the Company's normal operating cycle;
- b) it is held primarily for the purpose of being traded;
- c) it is expected to be realized within twelve months after the reporting date; or
- d) it is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting date.

All other assets are classified as non-current.

Liabilities:

A liability is classified as current when it satisfies any of the following criteria:

- a) it is expected to be settled in the Company's normal operating cycle;
 - b) it is held primarily for the purpose of being traded;
 - c) it is due to be settled within twelve months after the reporting date; or
 - d) the Company does not have an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.
- Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification.

All other liabilities are classified as non-current.

Current assets/ liabilities include the current portion of non-current assets/ liabilities respectively.

B) Measurement of fair values

The Company measures financial instruments at fair value at each Balance Sheet date.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- (i) In the principal market for the asset or liability, or
- (ii) In the absence of a principal market, in the most advantageous market for the asset or liability.

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

Level 1 - Quoted (unadjusted) market prices in active markets for identical assets or liabilities

Level 2 - Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable

Level 3 - Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable



United Ciigma Institute of Medical Sciences Private Limited

(All amounts are in ₹ millions, unless otherwise stated)

C) Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

a. Recognition and initial measurement

A financial asset or financial liability is initially measured at fair value plus, for an item not recorded at fair value through profit and loss (FVTPL), transaction costs that are directly attributable to its acquisition or issue.

b. Classification and subsequent measurement

Financial assets

On initial recognition, a financial asset is classified as measured at

- amortised cost; or
- fair value through profit or loss (either through other comprehensive income or through profit or loss). The classification depends upon the entity's business model for managing financial instruments and the contractual terms of the cash flows.

Financial assets are not reclassified subsequent to their initial recognition, except if and in the period the Company changes its business model for managing financial assets.

A financial asset is measured at amortised cost if it meets both of the following conditions and is not designated as at FVTPL.

- the asset is held within a business model whose objective is to hold assets to collect contractual cash flows; and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

A financial asset is measured at fair value through other comprehensive income (FVTOCI) if assets are held for collection of contractual cash flows and for selling the financial assets, where the assets' cash flows represent solely payments of principal and interest.

All financial assets not classified as measured at amortised cost or FVTOCI as described above are measured at FVTPL. This includes all derivative financial assets. On initial recognition, the Company may irrevocably designate a financial asset that otherwise meets the requirements to be measured at amortised cost or at FVTOCI as at FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise.

Financial assets: Assessment whether contractual cash flows are solely payments of principal and interest

For the purposes of this assessment, 'principal' is defined as the fair value of the financial asset on initial recognition. 'Interest' is defined as consideration for the time value of money and for the credit risk associated with the principal amount outstanding during a particular period of time and for other basic lending risks and costs (e.g. liquidity risk and administrative costs), as well as a profit margin.


In assessing whether the contractual cash flows are solely payments of principal and interest, the company considers the contractual terms of the instrument. This includes assessing whether the financial asset contains a contractual term that could change the timing or amount of contractual cash flows such that it would not meet this condition. In making this assessment, the company considers:

- contingent events that would change the amount or timing of cash flows;
- terms that may adjust the contractual coupon rate, including variable interest rate features;
- prepayment and extension features; and
- terms that limit the company's claim to cash flows from specified assets (e.g. non-recourse features).

A prepayment feature is consistent with the solely payments of principal and interest criterion if the prepayment amount substantially represents unpaid amounts of principal and interest on the principal amount outstanding, which may include reasonable additional compensation for early termination of the contract. Additionally, for a financial asset acquired at a significant discount or premium to its contractual par amount, a feature that permits or requires prepayment at an amount that substantially represents the contractual par amount plus accrued (but unpaid) contractual interest (which may also include reasonable additional compensation for early termination) is treated as consistent with this criterion if the fair value of the prepayment feature is insignificant at initial recognition.

Financial assets: Subsequent measurement and gains and losses

Financial assets at fair value	These assets are subsequently measured at fair value (either through profit or loss or other comprehensive income). Net gains and losses, including any interest or dividend income, are recognised in profit or loss.
Financial assets at amortised cost	These assets are subsequently measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognised in profit or loss. Any gain or loss on derecognition is recognised in profit or loss.



United Ciigma Institute of Medical Sciences Private Limited

(All amounts are in ₹ millions, unless otherwise stated)

Financial liabilities: Classification, subsequent measurement and gains and losses

Financial liabilities are classified as measured at amortised cost or FVTPL. A financial liability is classified as at FVTPL if it is classified as held-for-trading, or it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognised in profit or loss. Other financial liabilities are subsequently measured at amortised cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognised in profit or loss. Any gain or loss on derecognition is also recognised in profit or loss.

c. Derecognition

Financial assets

The Company derecognises a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Company neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control of the financial asset.

If the Company enters into transactions whereby it transfers assets recognised on its balance sheet, but retains either all or substantially all of the risks and rewards of the transferred assets, the transferred assets are not derecognised.

Financial liabilities

The Company derecognises a financial liability when its contractual obligations are discharged or cancelled, or expire.

The Company also derecognises a financial liability when its terms are modified and the cash flows under the modified terms are substantially different. In this case, a new financial liability based on the modified terms is recognised at fair value. The difference between the carrying amount of the financial liability extinguished and the new financial liability with modified terms is recognised in profit or loss.

d. Offsetting

Financial assets and financial liabilities are offset and the net amount presented in the balance sheet when, and only when, the Company currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the asset and settle the liability simultaneously.

D) Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and on hand and short-term deposits with an maturity of three months or less which are subject to insignificant risk of changes in value.

E) Cash flow statement

Cash flows are reported using the indirect method, whereby net profit/(loss) before tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated.

F) Revenue recognition


Revenue primarily comprises fees charged under contract for inpatient and/or outpatient hospital services and includes sale of medical and non-medical items. Hospital services include charges for accommodation, medical professional services, equipment, radiology, laboratory, pharmaceutical goods among others, used in treatments provided to the patients.

Revenue is recognized on satisfaction of performance obligation upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services.

The Company does not expect to have any contracts where the period between the transfer of the promised goods or services to the customer and payment by the customer exceeds one year. As a consequence, it does not adjust any of the transaction prices for the time value of money.

The Company satisfies a performance obligation and recognises revenue over time, if one of the following criteria is met:

- (i) the customer simultaneously receives and consumes the benefits provided by the Company's performance as the Company performs;
- (ii) the Company's performance creates or enhances an asset that the customer controls as the asset is created or enhanced;
- (iii) the Company's performance does not create an asset with an alternative use to the Company and an entity has an enforceable right to payment for performance completed to date.



For performance obligations where one of the above conditions are not met, revenue is recognised at the point in time at which the performance obligation is satisfied.

Goods and services tax is not received by the Company on its own account. Rather, it is tax collected by the Company on behalf of the Government. Accordingly, it is excluded from revenue.

Unbilled receivables and Unearned revenue

Contract assets are recognised when there is excess of revenue earned over billings on contracts. Contract assets are classified as unbilled receivables when there is unconditional right to receive cash, and only passage of time is required, as per contractual terms. Other contract assets have been disclosed as contract assets within other assets.

Unearned revenue ("contract liability") is recognised when there are billings in excess of revenues. The billing schedules agreed with customers could include periodic performance-based payments and/or milestone-based progress payments. Invoices are payable within contractually agreed credit period. Advances received for services are reported as liabilities until all conditions for revenue recognition are

G) Property, plant and equipment

Recognition and measurement

Property, plant and equipment are measured at cost, which includes capitalised borrowing costs, less accumulated depreciation and accumulated impairment losses, if any. The cost of an item of property, plant and equipment comprises its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates, any directly attributable cost of bringing the item to its working condition for its intended use and estimated costs of dismantling and removing the item and restoring the site on which it is located.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognised when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred.

If significant parts of an item of property, plant and equipment have different useful lives then they are accounted as separate items (major components) of property, plant and equipment.

Any gain or loss on disposal of an item of property, plant and equipment is recognised in statement of profit and loss account.

The cost and related accumulated depreciation are derecognised from the financial statements upon sale or disposition of the asset and the resultant gains or losses are recognised in the statement of profit and loss. Amount paid towards the acquisition of property, plant and equipment outstanding as of each reporting date are recognised as capital advance and the cost of property, plant and equipment not ready for intended use before such date are disclosed under capital work-in-progress.

H) Employee benefits

Short-term employee benefits

Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. A liability is recognised for the amount expected to be paid e.g., under short-term cash bonus, if the company has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee, and the amount of obligation can be estimated reliably.


Post-employment benefits

Defined contribution plans

A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and will have no legal or constructive obligation to pay further amounts. The Company makes specified monthly contributions towards employee provident fund to Government administered provident fund scheme which is a defined contribution plan. Obligations for contributions to defined contribution plans are recognised as an employee benefit expense in profit or loss in the periods during which the related services are rendered by employees.

Defined benefit plans

A defined benefit plan is a post-employment benefit plan other than a defined contribution plan. The Company's gratuity benefit scheme is a defined benefit plan. The Company's net obligation in respect of defined benefit plan is calculated by estimating the amount of future benefit that employees have earned in the current and prior periods, discounting that amount and deducting the fair value of any plan assets. The calculation of defined benefit obligation is performed annually by a qualified actuary using the projected unit credit method.



United Ciigma Institute of Medical Sciences Private Limited

(All amounts are in ₹ millions, unless otherwise stated)

The gratuity scheme is managed by third party administrators.

Remeasurements of the net defined benefit liability, which comprise actuarial gains and losses and the return on plan assets (excluding interest) are recognised in Other Comprehensive Income (OCI). The Company determines the net interest expense on the net defined benefit liability for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period to the then-net defined benefit liability/(asset), taking into account any changes in the net defined benefit liability during the period as a result of contributions and benefit payments. Net interest expense and other expenses related to defined benefit plans are recognised in the statement of profit and loss.

When the benefits of a plan are changed or when a plan is curtailed, the resulting change in benefit that relates to past service ('past service cost' or 'past service gain') or the gain or loss on curtailment is recognised immediately in profit or loss. The Company recognises gains and losses on the settlement of a defined benefit plan when the settlement occurs.

Compensated absences

The employees can carry-forward a portion of the unutilized accrued compensated absences and utilize it in future service periods or receive cash compensation on termination of employment. Considering the industry the company operates and requires employees to be available for emergency services, management has made an estimate of leaves availment by its employees to classify the benefit as short term or long term. The obligation is measured on the basis of independent actuarial valuation using the projected unit credit method.

I) Borrowing cost

Borrowing costs are interest and other costs (including exchange differences relating to foreign currency borrowings to the extent that they are regarded as an adjustment to interest costs) incurred in connection with the borrowing of funds. Borrowing costs directly attributable to acquisition or construction of an asset which necessarily take a substantial period of time to get ready for their intended use are capitalised as part of the cost of that asset. Other borrowing costs are recognised as an expense in the period in which they are incurred.

J) Earnings per equity share (EPES)

The basic earnings/(loss) per share is computed by dividing the net profit/(loss) attributable to equity shareholders for the period by the weighted average number of equity shares outstanding during the year.

The Company does not have potential dilutive equity shares outstanding during the reporting period.

K) Income tax

Income tax comprises current and deferred tax. It is recognised in profit or loss except to the extent that it relates to a business combination or to an item recognised directly in equity or in other comprehensive income.

Current tax

Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to the tax payable or receivable in respect of previous years. The amount of current tax reflects the best estimate of the tax amount expected to be paid or received after considering the uncertainty, if any, related to income taxes. It is measured using tax rates (and tax laws) enacted or substantively enacted by the reporting date.

Current tax assets and current tax liabilities are offset only if there is a legally enforceable right to set off the recognised amounts, and it is intended to realise the asset and settle the liability on a net basis or simultaneously.

Deferred tax

Deferred tax is recognised in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the corresponding amounts used for taxation purposes.


Deferred tax liabilities are recognised for all taxable temporary differences.

Deferred tax assets are recognised to the extent that it is probable that future taxable profits will be available against which they can be used. Deferred tax assets – unrecognised or recognised, are reviewed at each reporting date and are recognised/ reduced to the extent that it is probable/ no longer probable respectively that the related tax benefit will be realised.

Deferred tax is measured at the tax rates that are expected to apply to the period when the asset is realised or the liability is settled, based on the laws that have been enacted or substantively enacted by the reporting date.

The measurement of deferred tax reflects the tax consequences that would follow from the manner in which the company expects, at the reporting date, to recover or settle the carrying amount of its assets and liabilities.

Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realised simultaneously.



L) Impairment

a. Impairment of financial instruments

The Company recognises loss allowances for expected credit losses on financial assets measured at amortised cost; At each reporting date, the Company assesses whether financial assets carried at amortised cost are credit impaired. A financial asset is 'credit- impaired' when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred.

Evidence that a financial asset is credit- impaired includes the following observable data:

- significant financial difficulty of the borrower or issuer;
- the restructuring of a loan or advance by the Company on terms that the Company would not consider otherwise;
- it is probable that the borrower will enter bankruptcy or other financial reorganisation; or
- the disappearance of an active market for a security because of financial difficulties.

In accordance with Ind AS 109, the Company applies expected credit loss (ECL) model for measurement and recognition of impairment loss on the following financial assets and credit risk exposure:

Measurement of expected credit losses

Expected credit losses are a probability-weighted estimate of credit losses. Credit losses are measured as the present value of all cash shortfalls (i.e. the difference between the cash flows due to the Company in accordance with the contract and the cash flows that the Company expects to receive).

Presentation of allowance for expected credit losses in the balance sheet.

Loss allowances for financial assets measured at amortised cost are deducted from the gross carrying amount of the assets.

Write-off

The gross carrying amount of a financial asset is written off (either partially or in full) to the extent that there is no realistic prospect of recovery. This is generally the case when the Company determines that the trade receivable or the financial assets does not have assets or sources of income that could generate sufficient cash flows to repay the amounts subject to the write- off. However, financial assets that are written off could still be subject to enforcement activities in order to comply with the Company's procedures for recovery of amounts due.

b. Impairment of non-financial assets

The Company's non-financial assets, inventories and deferred tax assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated.

For impairment testing, assets that do not generate independent cash inflows are companied together into cash-generating units (CGUs). Each CGU represents the smallest company of assets that generates cash inflows that are largely independent of the cash inflows of other assets or CGUs.

The recoverable amount of a CGU (or an individual asset) is the higher of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the CGU (or the asset).

An impairment loss is recognised if the carrying amount of an asset or CGU exceeds its estimated recoverable amount. Impairment losses are recognised in the statement of profit and loss.

M) Provisions

Provisions are recognised when the company has a present obligation (legal or constructive) as a result of a past event, it is probable than an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. when the company expects some or all of the provisions to be reimbursed, the expenses relating to the provisions is presented in the statement of profit and loss net of any reimbursement.

If the effect of the time value of the money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provisions due to the passage of time is recognised as a finance cost.

N) Measurement of Earnings before interest, tax, depreciation and amortisation (EBITDA)

The Company has elected to present earnings before interest, tax, depreciation and amortization (EBITDA) as a separate line item on the face of the Statement of Profit and Loss. The Company measures EBITDA on the basis of profit/loss from operations. In its measurement of EBITDA, the Company includes other income but des not include depreciation and amortization expenses, finance cost and tax expense.



4.37 Financial ratios

S.No.	Particulars	For the year ended 31 March 2024		For the year ended 31 March 2023		Variance %	Reason if variance is more than 25%
		Amount	Ratio	Amount	Ratio		
1	Current ratio						
	Numerator - Current assets	508.29	1.87	386.42	1.76	6.25%	None
	Denominator - Current liabilities	271.21		219.31			
2	Debt-equity ratio						
	Numerator - Total debt	913.05	0.45	1,008.35	0.52	-13.46%	None
	Denominator - Total shareholders equity	2,039.93		1,933.42			
3	Debt service coverage ratio						
	Numerator - PAT + Depreciation and amortisations + Interest + Loss on property, plant and equipment + Provision for doubtful balances	347.93	1.91	341.98	0.64	198.44%	The change in ratio is mainly on account of reduction in repayment of borrowing as a result of closure of a particular loan in the previous year.
	Denominator - Interest & lease payments + principal repayments	182.21		532.52			
4	Return on equity ratio (in %)						
	Numerator - Profit after tax	106.40	5.36	72.00	6.06	-11.55%	None
	Denominator - Average shareholders equity	1,986.68		1,187.91			
5	Inventory turnover ratio (in times)						
	Numerator - Cost of goods sold	337.12	15.93	272.14	7.48	112.97%	The change in ratio is mainly on account of reduced inventory holding as at current year end when compared to previous year end.
	Denominator - Average Inventory	21.16		36.41			
6	Trade receivables turnover ratio (in times)						
	Numerator - Net credit sales	750.02	3.78	568.37	3.77	0.27%	None
	Denominator - Average trade receivables	198.43		150.85			
7	Trade payables turnover ratio (in times)						
	Numerator - Net credit purchases	1,002.08	11.75	814.03	9.24	27.16%	The change in ratio when compared to previous year is mainly on account of increase in credit purchases with no respective increase in closing trade payables due to better payments during the current year.
	Denominator - Average trade payables	85.28		88.13			
8	Net capital turnover ratio (in times)						
	Numerator - Revenue from operations	1,392.76	6.89	1,237.04	10.38	-33.62%	The change in ratio is mainly on account of increase in revenue during the current year and inventory written off during the previous year.
	Denominator - Average working capital	202.10		119.15			
9	Net profit ratio (in %)						
	Numerator - Profit for the year	106.40	7.64	72.00	5.82	31.27%	The change in ratio is mainly on account of increase in revenue during the current year and inventory written off during the previous year.
	Denominator - Revenue from operations	1,392.76		1,237.04			
10	Return on capital employed (in %)						
	Numerator - Profit before tax and finance costs	226.74	7.69	243.12	8.26	-6.90%	None
	Denominator - Capital employed= Tangible network + Total debt + Deferred tax liability	2,947.90		2,941.77			
11	Return on investment (in %)						
	Numerator - Earnings before interest and taxes	226.74	7.33	243.12	9.29	-21.10%	None
	Denominator - Average total assets	3,092.91		2,616.49			

For Price Waterhouse Chartered Accountants LLP
Firm's Registration No: 012754N/NS00016

Sudharmendra N
Partner
Membership No: 223014

Place: Hyderabad
Date: 21 August 2024

For and on behalf of Board of Directors of
United Cigma Institute of Medical Sciences Private Limited
CIN: U74120MH2011PTC213136

Dr. Umesh Takalkar
Managing director
DIN - 01578381
Place: Aurangabad
Date: 21 August 2024

Anand Venugopal
Chief Financial Officer
PAN - AKHPV3361Q
Place: Hyderabad
Date: 21 August 2024

Jadeep Singh
Director
DIN - 02705303
Place: Hyderabad
Date: 21 August 2024

Divyanki Sharma
Company Secretary
PAN - FSYP3605A
Place: Hyderabad
Date: 21 August 2024





WWW.CAREHOSPITALS.COM